[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 167
1. Dadu T, Rangan A, Handoo A, Bhargava M: Primary non-secretory plasma cell leukemia with atypical morphology - a case report. Indian J Hematol Blood Transfus; 2009 Jun;25(2):81-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-secretory plasma cell leukemia with atypical morphology - a case report.
  • Only one case of primary non-secretory plasma cell leukemia with atypical morphology has been reported thus far.
  • Here we report another such case of plasma cell leukemia diagnosed on fl ow cytometry, as morphological heterogeneity and lack of monoclonal immunoglobulins in both serum and urine, made it difficult to come to a conclusive diagnosis based purely on morphology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 1998 Sep;83(9):849-50 [9825580.001]
  • [Cites] Ann Hematol. 1999 Jan;78(1):25-7 [10037265.001]
  • [Cites] J Postgrad Med. 1998 Apr-Jun;44(2):47-9 [10703570.001]
  • [Cites] Jpn J Clin Oncol. 2003 May;33(5):232-7 [12865467.001]
  • [Cites] Indian J Pathol Microbiol. 2004 Oct;47(4):592-3 [16295407.001]
  • [Cites] Arch Pathol Lab Med. 2006 Aug;130(8):1212-5 [16879026.001]
  • [Cites] Indian J Pathol Microbiol. 2003 Jan;46(1):104-5 [15027746.001]
  • [Cites] J Leukoc Biol. 2004 Sep;76(3):528-36 [15155772.001]
  • [Cites] Haematologica. 2006 Sep;91(9):1234-40 [16956823.001]
  • (PMID = 23100981.001).
  • [ISSN] 0971-4502
  • [Journal-full-title] Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
  • [ISO-abbreviation] Indian J Hematol Blood Transfus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3452963
  • [Keywords] NOTNLM ; Electrophoresis / Flow cytometry / Multiple myeloma / Plasma cell leukemia
  •  go-up   go-down


2. Drake MB, Iacobelli S, van Biezen A, Morris C, Apperley JF, Niederwieser D, Björkstrand B, Gahrton G, European Group for Blood and Marrow Transplantation and the European Leukemia Net: Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica; 2010 May;95(5):804-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary plasma cell leukemia and autologous stem cell transplantation.
  • BACKGROUND: Primary plasma cell leukemia is a rare disorder accounting for less than 5% of malignant plasma cell diseases.
  • The results of conventional therapy are disappointing though autologous stem cell transplantation may improve survival.
  • DESIGN AND METHODS: A retrospective analysis was undertaken of the European Group for Blood and Marrow Transplantation experience of 272 patients with plasma cell leukemia and 20844 with multiple myeloma undergoing first autologous transplantation between 1980 and 2006.
  • RESULTS: There was no difference in type of graft or use of total body irradiation between patients with plasma cell leukemia and multiple myeloma, but the group with plasma cell leukemia was transplanted earlier after diagnosis (6.0 versus 7.7 months, P=0.000).
  • Patients with plasma cell leukemia were more likely to enter complete remission after transplantation but their overall survival (25.7 months, 95% confidence interval 19.5-31.9 months) was inferior to that of patients with multiple myeloma (62.3 months, 95% confidence interval 60.4-64.3 months) (P=0.000), due to the short duration of their post-transplant response and increased non-relapse-related mortality.
  • CONCLUSIONS: This largest study ever reported on plasma cell leukemia suggests that autologous transplantation can improve outcome, although results are markedly inferior to those achieved in patients with multiple myeloma, highlighting the need for novel approaches to this aggressive disorder.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Plasma Cell / mortality. Leukemia, Plasma Cell / surgery. Transplantation Conditioning

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1998 Jul;102(2):495-502 [9695964.001]
  • [Cites] Bone Marrow Transplant. 1997 Nov;20(10):901-4 [9404934.001]
  • [Cites] Bone Marrow Transplant. 1998 Oct;22(8):823-5 [9827984.001]
  • [Cites] Leukemia. 1998 Dec;12(12):1977-82 [9844928.001]
  • [Cites] Blood. 1999 Jan 1;93(1):55-65 [9864146.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1032-7 [9920853.001]
  • [Cites] Acta Haematol. 1999;101(4):193-6 [10436300.001]
  • [Cites] Pharmacotherapy. 2005 Dec;25(12):1820-5 [16305302.001]
  • [Cites] Leuk Lymphoma. 2006 Aug;47(8):1670-3 [16966282.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):180-2 [17325863.001]
  • [Cites] Br J Haematol. 1998 Sep;102(5):1115-23 [9753033.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3607-9 [10610115.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1259-72 [10626149.001]
  • [Cites] Blood. 2001 Feb 1;97(3):822-5 [11157506.001]
  • [Cites] Bone Marrow Transplant. 2001 Mar;27(5):511-5 [11313685.001]
  • [Cites] Clin Lab Haematol. 2003 Feb;25(1):55-8 [12542443.001]
  • [Cites] Arch Intern Med. 1974 May;133(5):813-8 [4821776.001]
  • [Cites] Mayo Clin Proc. 1975 Jan;50(1):29-40 [1110582.001]
  • [Cites] Lancet. 1983 Oct 8;2(8354):822-4 [6137651.001]
  • [Cites] Am J Med. 1987 Dec;83(6):1062-8 [3503574.001]
  • [Cites] Blood. 1991 Sep 1;78(5):1198-204 [1715218.001]
  • [Cites] Oncogene. 1992 Dec;7(12):2539-43 [1461658.001]
  • [Cites] Blood. 1993 Jan 1;81(1):128-35 [8417784.001]
  • [Cites] Blood. 1993 May 15;81(10):2708-13 [8490179.001]
  • [Cites] Br J Haematol. 1994 Dec;88(4):754-9 [7819100.001]
  • [Cites] Br J Haematol. 1995 Apr;89(4):914-6 [7772534.001]
  • [Cites] Blood. 1995 Jul 15;86(2):685-91 [7605999.001]
  • [Cites] Bone Marrow Transplant. 1996 Jul;18(1):225-7 [8832022.001]
  • [CommentIn] Haematologica. 2010 May;95(5):705-7 [20442443.001]
  • (PMID = 20442444.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ G0802523
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2864387
  •  go-up   go-down


3. Xu X, Broome EH, Rashidi HH, South ST, Dell'aquila ML, Wang HY: CD20dim-positive T-cell large granular lymphocytic leukemia in a patient with concurrent hairy cell leukemia and plasma cell myeloma. Int J Clin Exp Pathol; 2010;3(8):798-807
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD20dim-positive T-cell large granular lymphocytic leukemia in a patient with concurrent hairy cell leukemia and plasma cell myeloma.
  • We report a CD20dim- positive T-cell large granular lymphocytic (T-LGL) leukemia in a patient with concurrent hairy cell leukemia and plasma cell myeloma.
  • This patient was first diagnosed with T-LGL leukemia with dim CD20 expression, which by itself was a rare entity.
  • He received no treatment for T-LGL leukemia.
  • The patient later developed a hairy cell leukemia, which went into complete clinical remission after one cycle of 2-CdA.
  • Five years later, he was diagnosed with a third malignancy, plasma cell myeloma.
  • Complex cytogenetic aberrancies were present at the time when plasma cell myeloma was diagnosed.
  • [MeSH-major] Antigens, CD20 / metabolism. Leukemia, Hairy Cell / pathology. Leukemia, Large Granular Lymphocytic / metabolism. Leukemia, Large Granular Lymphocytic / pathology. Multiple Myeloma / pathology. Neoplasms, Multiple Primary / pathology

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2001 Feb;14(2):105-10 [11235901.001]
  • [Cites] Hum Pathol. 2010 Apr;41(4):461-76 [20226962.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1454-9 [12145685.001]
  • [Cites] Schweiz Med Wochenschr. 1980 Oct 11;110(41):1494-8 [6999621.001]
  • [Cites] Acta Haematol. 1984;72(1):57-60 [6433635.001]
  • [Cites] Cytometry. 1993;14(2):196-204 [7679964.001]
  • [Cites] Leukemia. 1993 Jun;7(6):782-8 [8388971.001]
  • [Cites] Am J Hematol. 1993 Nov;44(3):216-7 [8213782.001]
  • [Cites] Blood. 1994 May 15;83(10):2931-8 [8180388.001]
  • [Cites] Am J Clin Pathol. 1994 Oct;102(4):483-9 [7524302.001]
  • [Cites] Haematologica. 1995 Mar-Apr;80(2):146-9 [7543070.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1803-10 [9164188.001]
  • [Cites] Br J Haematol. 1998 Feb;100(2):291-4 [9488615.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1160-4 [9694703.001]
  • [Cites] Blood. 1958 Jul;13(7):609-30 [13560561.001]
  • [Cites] Am J Clin Pathol. 2007 Feb;127(2):176-81 [17210522.001]
  • [Cites] J Natl Cancer Inst. 2007 Feb 7;99(3):215-22 [17284716.001]
  • [Cites] Int J Hematol. 2007 Nov;86(4):348-51 [18055343.001]
  • [Cites] J Cutan Pathol. 2008 Apr;35(4):398-403 [18261116.001]
  • [Cites] Cancer Invest. 2008 Oct;26(8):860-5 [18798068.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4235-46 [18337559.001]
  • [Cites] Int J Lab Hematol. 2008 Oct;30(5):420-4 [19046317.001]
  • [Cites] Leuk Res. 2009 Jun;33(6):e13-6 [18995899.001]
  • [Cites] Intern Med. 2009;48(16):1443-7 [19687595.001]
  • [Cites] Leuk Lymphoma. 2001 Sep-Oct;42(5):1043-8 [11697621.001]
  • (PMID = 21151394.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC2993231
  • [Keywords] NOTNLM ; CD20 / T-cell large granular lymphocytic leukemia / hairy cell leukemia / plasma cell myeloma
  •  go-up   go-down


Advertisement
4. Chang H, Sloan S, Li D, Patterson B: Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization. Cancer Genet Cytogenet; 2005 Jan 15;156(2):150-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization.
  • A combination of cytoplasmic immunofluorescence to detect the immunoglobulin light chain and an interphase fluorescence in situ hybridization technique was used to study the recurrent genetic abnormalities in 14 patients with plasma cell leukemia (PCL).
  • The frequent TP53 deletions may represent a marker of genetic instability giving rise to an increased propensity for myeloma cells to emigrate from the bone marrow environment and enter leukemic phase.
  • [MeSH-major] Chromosome Aberrations. Interphase / genetics. Leukemia, Plasma Cell / genetics

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642395.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. Dosi RV, Ambaliya A, Patell RD, Joshi HJ: A rare case of plasma cell leukemia in a 35 year old. Indian J Med Sci; 2010 Jun;64(6):281-4
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of plasma cell leukemia in a 35 year old.
  • Plasma cell leukemia is a rare, aggressive form of multiple myeloma.
  • His complete blood count showed anemia and a high WBC count with atypical cells on peripheral smear.
  • Bone marrow examination showed more than 90% of atypical plasma cells, confirming a diagnosis of plasma cell leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Plasma Cell / drug therapy

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22885320.001).
  • [ISSN] 1998-3654
  • [Journal-full-title] Indian journal of medical sciences
  • [ISO-abbreviation] Indian J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 9PHQ9Y1OLM / Prednisolone; Q41OR9510P / Melphalan
  •  go-up   go-down


6. Kim SJ, Kim J, Cho Y, Seo BK, Kim BS: Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia. Jpn J Clin Oncol; 2007 May;37(5):382-4
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.
  • Plasma cell leukemia is a rare malignant plasma cell disorder characterized by proliferation of plasma cells in blood and the bone marrow, the outcome of which is poor with conventional therapy.
  • More effective treatment strategies are therefore needed for this disorder.
  • Here, we report a case of secondary plasma cell leukemia from Immunoglobulin D multiple myeloma refractory to doxorubicin-containing chemotherapy and thalidomide.
  • Complete remission was maintained until the fourth course of the treatment, and we then performed autologous peripheral blood stem cell transplantation.
  • Our experience suggests that combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be an effective induction treatment for plasma cell leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Plasma Cell / drug therapy

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17538191.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


7. Musto P, Rossini F, Gay F, Pitini V, Guglielmelli T, D'Arena G, Ferrara F, Filardi N, Guariglia R, Palumbo A, GISMM Cooperative Group, GISL Cooperative Group, GIMEMA Cooperative Group: Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer; 2007 Jun 1;109(11):2285-90
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of bortezomib in patients with plasma cell leukemia.
  • BACKGROUND: The prognosis of patients with plasma cell leukemia (PCL), an aggressive variant of multiple myeloma (MM), is usually poor.
  • Three patients were treated with bortezomib as frontline therapy, and 9 patients received bortezomib after 1 to 4 lines of chemotherapy, including autologous stem cell transplantation and thalidomide.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Leukemia, Plasma Cell / drug therapy. Pyrazines / therapeutic use
  • [MeSH-minor] Aged. Bortezomib. Female. Humans. Male. Middle Aged. Retrospective Studies. Stem Cell Transplantation. Survival Rate

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17469169.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


8. Sher T, Miller KC, Deeb G, Lee K, Chanan-Khan A: Plasma cell leukaemia and other aggressive plasma cell malignancies. Br J Haematol; 2010 Aug;150(4):418-27
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukaemia and other aggressive plasma cell malignancies.
  • Extramedullary plasma cell cancers, such as plasma cell leukaemia (PCL) and multiple extramedullary plasmacytomas (MEP) are very aggressive malignancies.
  • These can be primary (de-novo) or secondary due to progressive prior multiple myeloma (MM).
  • Markers of poor prognosis are frequently observed in these extramedullary forms of plasma cell cancers, and survival is significantly inferior compared to patients with MM.
  • Even high dose chemotherapy with autologous stem cell rescue has not been able to demonstrate consistent improvement in survival outcome.
  • Although not specifically evaluated, novel anti-plasma cell agents, such as the proteasome inhibitor bortezomib, and immunomodulatory drugs, such as lenalidomide, appear to be active against these aggressive cancers.
  • Clinical and translational research directed at improved understanding of disease biology and development of novel therapeutics is urgently needed.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Bortezomib. Female. Humans. Leukemia, Plasma Cell / diagnosis. Leukemia, Plasma Cell / drug therapy. Leukemia, Plasma Cell / etiology. Male. Middle Aged. Prognosis. Pyrazines / therapeutic use. Thalidomide / analogs & derivatives. Thalidomide / therapeutic use

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rinsho Ketsueki. 1987 Mar;28(3):428-33 [3613131.001]
  • [Cites] Clin Lymphoma Myeloma. 2009 Aug;9(4):328-30 [19717386.001]
  • [Cites] Eur J Haematol Suppl. 1989;51:76-83 [2697596.001]
  • [Cites] Rinsho Ketsueki. 1991 Apr;32(4):399-403 [2067085.001]
  • [Cites] Dtsch Med Wochenschr. 1992 Jun 5;117(23):900-4 [1597118.001]
  • [Cites] Anticancer Res. 1993 Jul-Aug;13(4):1091-5 [8352531.001]
  • [Cites] Am J Hematol. 1994 Mar;45(3):262-4 [8296801.001]
  • [Cites] Rinsho Ketsueki. 1994 Aug;35(8):756-60 [7933562.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2398-404 [7964956.001]
  • [Cites] Br J Haematol. 1994 Dec;88(4):754-9 [7819100.001]
  • [Cites] Br J Haematol. 1995 Apr;89(4):914-6 [7772534.001]
  • [Cites] Br J Haematol. 1996 May;93(2):345-51 [8639427.001]
  • [Cites] Leuk Lymphoma. 1997 May;25(5-6):545-54 [9250826.001]
  • [Cites] Am J Hematol. 1998 Jan;57(1):51-6 [9423817.001]
  • [Cites] Leukemia. 1998 Dec;12(12):1977-82 [9844928.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1032-7 [9920853.001]
  • [Cites] Br J Haematol. 1999 Jan;104(1):138-43 [10027726.001]
  • [Cites] Br J Haematol. 1999 Jul;106(1):28-34 [10444159.001]
  • [Cites] Blood. 1953 Jun;8(6):519-23 [13059037.001]
  • [Cites] Leukemia. 2005 Mar;19(3):449-55 [15674420.001]
  • [Cites] Am J Hematol. 2005 Apr;78(4):288-94 [15795922.001]
  • [Cites] Ann Hematol. 2006 Apr;85(4):263-7 [16416115.001]
  • [Cites] Leukemia. 2006 Mar;20(3):542-5 [16408097.001]
  • [Cites] Ann Hematol. 2006 Jul;85(7):487-8 [16570151.001]
  • [Cites] Leuk Lymphoma. 2006 Aug;47(8):1670-3 [16966282.001]
  • [Cites] Leuk Res. 2006 Dec;30(12):1581-3 [16540168.001]
  • [Cites] Haematologica. 2007 Jan;92(1):143-4 [17229655.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):180-2 [17325863.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2285-90 [17469169.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1423-5 [17613775.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1426-8 [17613776.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2516-20 [17975015.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Gan To Kagaku Ryoho. 2008 Mar;35(3):533-7 [18347412.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1544-52 [18285605.001]
  • [Cites] Leuk Res. 2008 Jul;32(7):1153-6 [18083228.001]
  • [Cites] Bone Marrow Transplant. 2008 May;41(9):779-84 [18195681.001]
  • [Cites] Leukemia. 2008 May;22(5):1044-52 [18216867.001]
  • [Cites] Med Oncol. 2008;25(2):154-60 [18488157.001]
  • [Cites] Leuk Res. 2008 Oct;32(10):1637-8 [18433866.001]
  • [Cites] Ann Oncol. 1999 Oct;10(10):1249-50 [10586345.001]
  • [Cites] Lancet. 2000 Jan 22;355(9200):248-50 [10675068.001]
  • [Cites] Blood. 2001 Feb 1;97(3):822-5 [11157506.001]
  • [Cites] Ann Hematol. 2002 Feb;81(2):119-23 [11907796.001]
  • [Cites] Leuk Lymphoma. 2002 Feb;43(2):351-4 [11999568.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):882-5 [12060125.001]
  • [Cites] Ann Hematol. 2002 Jul;81(7):362-7 [12185504.001]
  • [Cites] J Bone Miner Res. 2002 Nov;17(11):1921-5 [12412796.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2377-80 [12424198.001]
  • [Cites] Leuk Lymphoma. 2003 Feb;44(2):379-80 [12688365.001]
  • [Cites] Arch Pathol Lab Med. 2003 Aug;127(8):1026-7 [12873179.001]
  • [Cites] Nihon Naika Gakkai Zasshi. 2004 Jan 10;93(1):139-41 [14968586.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1546-58 [14989251.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):735-8 [15160948.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):821-4 [15160964.001]
  • [Cites] Can Med Assoc J. 1977 Oct 8;117(7):788-9 [907952.001]
  • [Cites] N Engl J Med. 2008 Aug 28;359(9):906-17 [18753647.001]
  • [Cites] Cancer Causes Control. 2008 Oct;19(8):841-58 [18365759.001]
  • [Cites] Leuk Res. 2009 Feb;33(2):259-62 [18676019.001]
  • [Cites] Acta Haematol. 2009;121(1):47-51 [19339770.001]
  • [Cites] Int J Lab Hematol. 2009 Jun;31(3):338-43 [18284415.001]
  • [Cites] Leuk Res. 2009 Aug;33(8):1137-40 [19250676.001]
  • [Cites] Ann Oncol. 2010 Feb;21(2):325-30 [19633044.001]
  • [Cites] Am J Med. 1987 Dec;83(6):1062-8 [3503574.001]
  • (PMID = 20701603.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA121044
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 4Z8R6ORS6L / Thalidomide; 69G8BD63PP / Bortezomib; F0P408N6V4 / lenalidomide
  • [Number-of-references] 69
  • [Other-IDs] NLM/ NIHMS585047; NLM/ PMC4044724
  •  go-up   go-down


9. Jaskiewicz AD, Herrington JD, Wong L: Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia. Pharmacotherapy; 2005 Dec;25(12):1820-5
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia.
  • Tumor lysis syndrome in plasma cell malignancies is less common due to the low turnover rate of the malignant B cells.
  • We describe the case of a patient with plasma cell leukemia treated with bortezomib who developed TLS.
  • Patients receiving bortezomib may be at risk for TLS, especially if they have high tumor burden, rapidly proliferative disease, and unfavorable cytogenetics.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Boronic Acids / adverse effects. Leukemia, Plasma Cell / drug therapy. Pyrazines / adverse effects. Tumor Lysis Syndrome / etiology

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pharmacotherapy. 2006 Aug;26(8):1205-6; discussion 1206 [16863501.001]
  • (PMID = 16305302.001).
  • [ISSN] 0277-0008
  • [Journal-full-title] Pharmacotherapy
  • [ISO-abbreviation] Pharmacotherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


10. John S, Feroze M, Supriya NK, Aisabi KA: Plasma cell leukemia with pleomorphic plasma cells--a case report. Indian J Pathol Microbiol; 2006 Jul;49(3):438-9
Genetic Alliance. consumer health - Plasma cell leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukemia with pleomorphic plasma cells--a case report.
  • A case of plasma cell leukemia showing mostly pleomorphic plasma cells in the form of convoluted and multilobated nuclei with some having bilobed nuclei and internuclear bridges is being reported for its rarity of occurrence.
  • Patient is in remission 5 months after diagnosis.
  • The significance of recognising such pleomorphic plasma cells is discussed.
  • [MeSH-major] Leukemia, Plasma Cell / diagnosis
  • [MeSH-minor] Bence Jones Protein / urine. Diagnosis, Differential. Electrophoresis. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Indian J Pathol Microbiol. 2007 Jan;50(1):45
  • (PMID = 17001915.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 9006-99-9 / Bence Jones Protein
  •  go-up   go-down


11. Peijing Q, Yan X, Yafei W, Dehui Z, Zengjun L, Junyuan Q, Yaozhong Z, Lugui Q: A retrospective analysis of thirty-one cases of plasma cell leukemia from a single center in China. Acta Haematol; 2009;121(1):47-51
Genetic Alliance. consumer health - Plasma cell leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective analysis of thirty-one cases of plasma cell leukemia from a single center in China.
  • BACKGROUND/AIMS: The study was undertaken to understand the characteristic of plasma cell leukemia (PCL) in China.
  • [MeSH-major] Leukemia, Plasma Cell / mortality
  • [MeSH-minor] Adult. Aged. Bone Marrow / pathology. China. Chromosome Aberrations. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 S. Karger AG, Basel.
  • (PMID = 19339770.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


12. Ramsingh G, Mehan P, Luo J, Vij R, Morgensztern D: Plasma cell leukemia: A SEER database analysis. J Clin Oncol; 2009 May 20;27(15_suppl):8605

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukemia: A SEER database analysis.
  • : 8605 Background: Primary plasma cell leukemia (PCL) is a rare plasma cell disorder with clinical information limited to small series of patients.
  • Patients were divided into cohorts based upon age, gender, race and time period of diagnosis.
  • Median overall survival (OS) and disease specific survivals (DSS, defined by interval from diagnosis to the event of death from PCL) were 4 months and 6 months respectively.
  • The poor long term outcome and the lack of improvement in survival of patients with PCL despite small gains in MM suggest a more aggressive disease, for which further therapeutic agents are needed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962618.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Oka S, Yokote T, Akioka T, Hara S, Yamano T, Okabe T, Arishiro K, Hoshiga M, Shimizu A, Tsuji M, Hanafusa T: [Effective measurement of coronary flow velocity reserve (CFVR) with transthoracic Doppler echocardiography (TTDE) for plasma cell leukemia with hyperviscosity syndrome]. Rinsho Ketsueki; 2006 Jan;47(1):16-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effective measurement of coronary flow velocity reserve (CFVR) with transthoracic Doppler echocardiography (TTDE) for plasma cell leukemia with hyperviscosity syndrome].
  • The laboratory findings showed increased white blood cells with abnormal cells, and serum immunofixation test showed monoclonal IgM kappa paraprotein.
  • On flow cytometric immunophenotyping with CD38 gating, most of the abnormal cells expressed surface CD20, CD138, cytoplasmic IgM, but neither surface CD56 nor surface IgM.
  • Immunohistochemical staining of abnormal cells was positive for surface CD38, surface CD20 and cytoplasmic IgM.
  • The final diagnosis was plasma cell leukemia IgM kappa type.
  • Two courses of VAD therapy were administered, then the condition improved, the serum IgM level decreased, abnormal cells were decreased in peripheral blood and bone marrow aspirates, and the creatinine levels improved.
  • [MeSH-major] Blood Viscosity. Coronary Circulation. Echocardiography, Doppler. Leukemia, Plasma Cell / blood. Leukemia, Plasma Cell / physiopathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood Flow Velocity. Bone Marrow Cells / pathology. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Electrocardiography. Female. Humans. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16479978.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; VAD protocol
  •  go-up   go-down


14. Kar R, Dutta S, Bhargava R, Kumar R, Pati HP: Immunoglobulin free light chains: do they have a role in plasma cell leukemia? Hematology; 2008 Dec;13(6):344-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoglobulin free light chains: do they have a role in plasma cell leukemia?
  • The assay of serum free light chains (FLCs) is established in the diagnosis and prognosis of several plasma cell dyscrasias, but its significance in plasma cell leukemia (PCL) has not been reported so far.
  • PCL is a rare and aggressive disease with a poor prognosis.
  • [MeSH-minor] Adult. Aged. Disease Progression. Fatal Outcome. Female. Humans. Kidney Diseases. Leukemia, Plasma Cell. Male. Middle Aged. Paraproteinemias. beta 2-Microglobulin / blood

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19055862.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains; 0 / beta 2-Microglobulin
  •  go-up   go-down


15. Xu W, Li JY, Fan L, Chen LJ, Qiu HR, Wang R, Qiao C, Lu H: [Detection of chromosome 13 deletion in plasma cell leukemia by dual-color fluorescence in situ hybridization]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec;16(6):1261-4
Genetic Alliance. consumer health - Plasma cell leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of chromosome 13 deletion in plasma cell leukemia by dual-color fluorescence in situ hybridization].
  • This study was aimed to investigate the deletion features of chromosome 13 in plasma cell leukemia (PCL) and its relationship with clinical features.
  • The number of 13q14 deletion cells ranged from 52% to 98%.
  • The number of cells with 13q31 deletion ranged from 50% to 98%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19099623.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


16. Mele G, Pinna S, Melpignano A, Quarta G: Retrospective case series of three patients with plasma cell leukemia treated with bortezomib-based regimens. Clin Ther; 2010 May;32(5):915-9
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective case series of three patients with plasma cell leukemia treated with bortezomib-based regimens.
  • BACKGROUND: Data from the literature have suggested that bortezomib is the only effective agent in the treatment of plasma cell leukemia (PCL), a type of plasma cell dyscrasia characterized by poor prognosis despite conventional chemotherapy including autologous and allogeneic transplantation.
  • In all 3 patients, circulating plasma cells persisted.
  • Patients 1 and 2 were not considered candidates for autologous peripheral blood stem cell transplantation (PBSCT) because of their nonresponse to the bortezomib-based regimens and severe deterioration of their clinical conditions (kidney and liver failure) due to disease progression.
  • After further treatment according to the modified protocol for patients with acute lymphatic leukemia (cyclophosphamide 800 mg/m2 i.v. on day 1 and 200 mg/m2 i.v. on days 2-5; vincristine 1.5 mg/m2 i.v. once daily on days 1, 8, and 15; doxorubicin 40 mg/m2 i.v. on day 1; methotrexate 1200 mg/m2/h i.v.
  • The patient died 5 months later because of disease progression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Boronic Acids / administration & dosage. Leukemia, Plasma Cell / drug therapy. Pyrazines / administration & dosage

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Excerpta Medica Inc. All rights reserved.
  • (PMID = 20685499.001).
  • [ISSN] 1879-114X
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


17. Goyal M, Mohammad N, Palanki SD, Vaniawala SN: Primary plasma cell leukemia with light chain secretion and multiple chromosomal abnormalities: How successfully treated? - A case report with review of literature. Indian J Med Paediatr Oncol; 2010 Jul;31(3):96-100

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary plasma cell leukemia with light chain secretion and multiple chromosomal abnormalities: How successfully treated? - A case report with review of literature.
  • Primary plasma cell leukemia is a rare form of plasma cell dyscrasia.
  • We present a case which had leukocytosis with numerous circulating plasma cells in the peripheral blood.
  • The patient was given chemotherapy and was subjected to autologous stem cell transplant, after which she is in complete remission till date.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1259-72 [10626149.001]
  • [Cites] Ann Hematol. 1992 Aug;65(2):88-90 [1511063.001]
  • [Cites] Am J Hematol. 2005 Apr;78(4):288-94 [15795922.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):5-6 [17325841.001]
  • [Cites] Eur J Haematol Suppl. 1989;51:76-83 [2697596.001]
  • [Cites] Semin Hematol. 1987 Jul;24(3):202-8 [3116673.001]
  • [Cites] Cancer Res. 1983 Feb;43(2):905-12 [6401225.001]
  • [Cites] Mayo Clin Proc. 2007 Oct;82(10):1179-84 [17908524.001]
  • [Cites] Leukemia. 2008 Jul;22(7):1343-53 [18509355.001]
  • [Cites] Leuk Lymphoma. 1996 Mar;21(1-2):25-30 [8907265.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1032-7 [9920853.001]
  • [Cites] Arch Intern Med. 1974 May;133(5):813-8 [4821776.001]
  • [Cites] Eur J Cancer. 1993;29A(9):1269-73 [8343266.001]
  • (PMID = 21206718.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3009444
  • [Keywords] NOTNLM ; Flow cytometry / fluorescent in-situ hybridization / free light chains / primary plasma cell leukemia / transplant
  •  go-up   go-down


18. Telek B, Méhes L, Batár P, Kiss A, Udvardy M: [Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation]. Orv Hetil; 2008 Oct 12;149(41):1957-9
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation].
  • [Transliterated title] Autológ ossejt-transzplantációt követoen kialakult plazmasejtes leukémia hatékony kezelése PAD- (bortezomib, doxorubicin, dexamethason) protokoll alkalmazásával.
  • The most aggressive and rare manifestation of multiple myeloma is plasma cell leukaemia (PCL).
  • While secondary form of PCL represents those heavily pretreated cases when leukaemic transformation develops terminally after intensive chemotherapy in patients with multiple myeloma, primary cases are characterized by leukaemic symptoms present at diagnosis.
  • The authors present a case of a patient with non-secretory multiple myeloma who had developed plasma cell leukaemia after peripheral stem cell transplantation.
  • Combination of PAD treatment with autologous and/or allogenic stem cell transplantation might further improve patients' outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Plasma Cell / drug therapy. Leukemia, Plasma Cell / etiology. Multiple Myeloma / complications. Peripheral Blood Stem Cell Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18842514.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Hormonal; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin
  •  go-up   go-down


19. Pérez-Andres M, Almeida J, Martin-Ayuso M, Moro MJ, Martin-Nuñez G, Galende J, Hernandez J, Mateo G, San Miguel JF, Orfao A, Spanish Network on Multiple Myeloma, Spanish Network of Cancer Research Centers: Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire. Cancer; 2006 Mar 15;106(6):1296-305
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire.
  • BACKGROUND: The majority of studies published to date regarding the role of the bone marrow (BM) microenvironment in the pathogenesis of monoclonal gammopathies (MG) have focused on the interaction between stroma cells and plasma cells, whereas information concerning the lymphocytes infiltrating the tumor microenvironment is scanty.
  • METHODS: The authors measured the distribution, TCR-Vbeta repertoire, immunophenotype, and functional characteristics of different subsets of BM T lymphocytes from 61 nontreated patients with MG (30 patients with MG of undetermined significance [MGUS], 27 patients with multiple myeloma [MM], and 4 patients with plasma cell leukemia [PCL]).
  • RESULTS: The authors found a significantly increased rate of BM infiltration by T cells in all patient groups, at the expense of CD4+CD8- and CD4-CD8- T lymphocytes and both CD4+CD28- and CD8+CD28- cytotoxic/effector T cell subsets, and associated with TCR-Vbeta expansions in both CD4+ and CD8+ BM T cells in the majority of patients with MGUS, MM, and PCL.
  • Moreover, the percentage of T cells secreting interferon (IFN)-gamma was found to be increased (P < or = 0.05) both in CD4+ and CD8+ T cells in MGUS and MM patients, and a higher plasma concentration of IFN-gamma was found in patients with MM.
  • It is interesting to note that a positive correlation was noted between the proportion of CD28- and both the percentage of IFN-gamma-secreting cells and the proportion of expanded TCR-Vbeta lymphocytes within the total BM CD4+ T cells.
  • CONCLUSIONS: The results of the current study demonstrated an increased infiltration of BM by T cells associated with frequent TCR-Vbeta expansions and a more prominent cytotoxic/Th1 phenotype in all the patient groups studied.
  • [MeSH-major] Leukemia, Plasma Cell / immunology. Multiple Myeloma / immunology. Paraproteinemias / immunology. Receptors, Antigen, T-Cell, alpha-beta / metabolism. T-Lymphocytes, Cytotoxic / immunology. Th1 Cells / immunology
  • [MeSH-minor] Aged. Antigens, CD / analysis. Bone Marrow Cells / immunology. Case-Control Studies. Female. Humans. Immunophenotyping. Interferon-gamma / secretion. Lymphocyte Count. Lymphocytes, Tumor-Infiltrating / immunology. Lymphocytes, Tumor-Infiltrating / metabolism. Lymphocytes, Tumor-Infiltrating / pathology. Male

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16475149.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Receptors, Antigen, T-Cell, alpha-beta; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


20. Ho V, Shearer A, Jagusch M: Pathological rupture of the spleen in uncomplicated myeloma. Clin Med Case Rep; 2008;1:19-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plasma cell leukaemias have been previously documented to present with splenic rupture.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24179339.001).
  • [ISSN] 1178-6450
  • [Journal-full-title] Clinical medicine. Case reports
  • [ISO-abbreviation] Clin Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3785339
  • [Keywords] NOTNLM ; myeloma / rupture / spleen
  •  go-up   go-down


21. Armellini A, Sarasquete ME, García-Sanz R, Chillón MC, Balanzategui A, Alcoceba M, Fuertes M, López R, Hernández JM, Fernández-Calvo J, Sierra M, Megido M, Orfão A, Gutiérrez NC, González M, San Miguel JF: Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma. Br J Haematol; 2008 Apr;141(2):212-5
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RAN, ZHX2 and RCBTB2 (CHC1L) expression was evaluated by quantitative real time reverse transcription polymerase chain reaction in plasma cells from 85 monoclonal gammopathies: 58 symptomatic multiple myeloma (MM) (52 untreated, six relapsed), eight smouldering MM, five monoclonal gammopathy of undetermined significance, four plasma cell leukaemias and 10 myeloid cell lines.
  • ZHX2 was weakly expressed in high-risk/proliferative disease compared to low-risk or indolent disease.
  • RCBTB2 expression was weaker in hyperdiploid versus non-hyperdiploid cases while RAN was more expressed in symptomatic MM and cell lines.
  • [MeSH-minor] Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Cells / metabolism. Female. Gene Expression. Gene Expression Profiling / methods. Humans. Male. Middle Aged. Paraproteinemias / drug therapy. Paraproteinemias / metabolism. Plasma Cells / metabolism. Prognosis. Reverse Transcriptase Polymerase Chain Reaction / methods. Treatment Outcome. ran GTP-Binding Protein / genetics. ran GTP-Binding Protein / metabolism

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18353163.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Homeodomain Proteins; 0 / Neoplasm Proteins; 0 / RAN protein, human; 0 / RCBTB2 protein, human; 0 / Transcription Factors; 0 / ZHX2 protein, human; EC 3.6.5.2 / ran GTP-Binding Protein
  •  go-up   go-down


22. Rodriguez C, Pont JC, Gouin-Thibault I, Andrieu AG, Molina T, Le Tourneau A, Le Garff-Tavernier M, Siguret V, Chaibi P: [Plasma cell leukaemia]. Ann Biol Clin (Paris); 2005 Sep-Oct;63(5):535-9
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Plasma cell leukaemia].
  • [Transliterated title] La leucémie à plasmocytes.
  • We report a case of primary plasma cell leukaemia, with an absolute count of plasma cells of 53 Giga/L, diagnosed in a 83-year-old woman.
  • The patient's condition improved, with no circulating plasma cells after 3 weeks of treatment, in response to the combination of thalidomide and dexamethasone administered for 5 days followed by thalidomide alone.
  • The clinical presentation, the morphological, flow cytometric and pathophysiological characteristics of the plasma cell leukaemia and the treatment are summarised in this paper.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Leukemia, Plasma Cell / diagnosis. Thalidomide / therapeutic use

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16230292.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Anti-Inflammatory Agents; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


23. Cha CH, Park CJ, Huh JR, Chi HS, Suh CW, Kang YK: Significantly better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia. Acta Haematol; 2007;118(3):178-82
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significantly better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia.
  • Plasma cell leukemia (PCL) is a rare variant of multiple myeloma (MM).
  • Patients may either present de novo (primary PCL), or PCL may occur during the course of MM (secondary PCL).
  • Primary PCL might be a differently developed disease from MM.
  • [MeSH-major] Leukemia, Plasma Cell / mortality. Leukemia, Plasma Cell / pathology. Multiple Myeloma / mortality. Multiple Myeloma / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Gene Expression Regulation, Leukemic. HLA-DR Antigens / biosynthesis. Humans. Male. Middle Aged. Neoplasm Proteins / biosynthesis. Platelet Count. Prognosis. Proto-Oncogene Proteins c-kit / biosynthesis. Retrospective Studies

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 S. Karger AG, Basel
  • (PMID = 17934254.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / HLA-DR Antigens; 0 / Neoplasm Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


24. Chiecchio L, Dagrada GP, White HE, Towsend MR, Protheroe RK, Cheung KL, Stockley DM, Orchard KH, Cross NC, Harrison CJ, Ross FM, UK Myeloma Forum: Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes Cancer; 2009 Jul;48(7):624-36
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent upregulation of MYC in plasma cell leukemia.
  • Plasma cell leukemia (PCL) is a rare form of monoclonal gammopathy, which can originate de novo or evolve from multiple myeloma (MM) as a terminal leukemic phase.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Leukemia, Plasma Cell / genetics. Proto-Oncogene Proteins c-myc / genetics

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19396865.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myc; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


25. Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, Chng WJ, Ketterling RP, Gertz MA, Henderson K, Greipp PR, Dispenzieri A, Lacy MQ, Rajkumar SV, Bergsagel PL, Stewart AK, Fonseca R: Genetic aberrations and survival in plasma cell leukemia. Leukemia; 2008 May;22(5):1044-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic aberrations and survival in plasma cell leukemia.
  • Plasma cell leukemia (PCL) is an aggressive and rare hematological malignancy that originates either as primary disease (pPCL) or as a secondary leukemic transformation (sPCL) of multiple myeloma (MM).

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1994 Dec;88(4):754-9 [7819100.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4457-63 [9616139.001]
  • [Cites] EMBO J. 1998 Sep 1;17(17):5001-14 [9724636.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1032-7 [9920853.001]
  • [Cites] Hum Mol Genet. 1999 Feb;8(2):185-93 [9931326.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):957-68 [10491521.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jan 15;156(2):150-3 [15642395.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2837-40 [15976175.001]
  • [Cites] Leukemia. 2004 Mar;18(3):654-7 [14712294.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2598-606 [15197802.001]
  • [Cites] Arch Intern Med. 1974 May;133(5):813-8 [4821776.001]
  • [Cites] J Natl Cancer Inst. 1977 May;58(5):1247-53 [857025.001]
  • [Cites] Blood. 1981 Feb;57(2):333-8 [7448427.001]
  • [Cites] Am J Med. 1987 Dec;83(6):1062-8 [3503574.001]
  • [Cites] Acta Oncol. 1990;29(1):1-8 [2178649.001]
  • [Cites] Blood. 1990 Apr 15;75(8):1684-90 [2183888.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1990 Jul;12(4):314-7 [2272272.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10325-9 [8234293.001]
  • [Cites] Science. 1994 Jul 15;265(5170):346-55 [8023157.001]
  • [Cites] Leuk Lymphoma. 2006 Feb;47(2):285-9 [16321859.001]
  • [Cites] Leuk Res. 2006 Mar;30(3):262-5 [16112193.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):950-6 [16404744.001]
  • [Cites] Leukemia. 2007 Mar;21(3):582-4 [17215851.001]
  • [Cites] Leukemia. 1999 Dec;13(12):2099-103 [10602435.001]
  • [Cites] Leuk Lymphoma. 1999 Nov;35(5-6):599-605 [10609798.001]
  • [Cites] Oncogene. 1999 Dec 13;18(53):7621-36 [10618702.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3560-8 [11071655.001]
  • [Cites] Blood. 2001 Feb 1;97(3):822-5 [11157506.001]
  • [Cites] Leuk Res. 2001 Feb;25(2):103-7 [11166824.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2816-21 [11306450.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):4990-5 [11309512.001]
  • [Cites] Biochem J. 2001 Jul 15;357(Pt 2):427-35 [11439092.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1271-2 [11510469.001]
  • [Cites] Hum Mutat. 2001 Sep;18(3):212-24 [11524732.001]
  • [Cites] Eur J Haematol. 2001 Jul;67(1):51-3 [11553267.001]
  • [Cites] Blood. 2001 Oct 1;98(7):2266-8 [11568015.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):715-20 [11830525.001]
  • [Cites] Hum Mutat. 2002 Apr;19(4):334-42 [11933188.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2750-61 [11965548.001]
  • [Cites] Mol Cell Biol. 2002 Jun;22(11):3842-51 [11997518.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1417-24 [12149226.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4569-75 [12576322.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8424-9 [12826609.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2562-7 [12805059.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Nov;38(3):234-9 [14506697.001]
  • (PMID = 18216867.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA083724; United States / NCI NIH HHS / CA / P50 CA100707-060008; United States / NCI NIH HHS / CA / P01 CA062242-13; United States / NCI NIH HHS / CA / CA21115-25C; United States / NCI NIH HHS / CA / P01 CA62242; United States / NCI NIH HHS / CA / U10 CA021115; United States / NIA NIH HHS / AG / R01 AG020686; United States / NIA NIH HHS / AG / R01 AG020686-05; United States / NCI NIH HHS / CA / CA100707-060008; United States / NCI NIH HHS / CA / P01 CA062242; United States / NCI NIH HHS / CA / P50 CA100707; United States / NCI NIH HHS / CA / R01 CA83724-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS79721; NLM/ PMC3893817
  •  go-up   go-down


26. Esparís-Ogando A, Alegre A, Aguado B, Mateo G, Gutiérrez N, Bladé J, Schenkein D, Pandiella A, San Miguel JF: Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer; 2005 Apr 20;114(4):665-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib is an efficient agent in plasma cell leukemias.
  • Plasma cell leukemia (PCL) represents the most aggressive form of monoclonal gammopathy for which new treatment approaches are needed.
  • Here we report the effect of Bortezomib on cells from 4 patients with PCL, as well as the in vivo efficacy on a patient with secondary PCL.
  • Bortezomib reduced PCL numbers and was more efficient in cell growth inhibition than dexamethasone or doxorubicin.
  • Following Bortezomib treatment, circulating plasma cells disappeared; what is more striking, the peripheral blood counts returned to normal, becoming transfusion-independent.
  • [MeSH-major] Boronic Acids / therapeutic use. Leukemia, Plasma Cell / drug therapy. Pyrazines / therapeutic use
  • [MeSH-minor] Anemia / drug therapy. Antineoplastic Agents / pharmacology. Apoptosis. Blotting, Western. Bortezomib. Caspase 3. Caspases / biosynthesis. Cell Proliferation. Cell Survival. Female. Humans. Middle Aged. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Multiple Myeloma / drug therapy. Poly(ADP-ribose) Polymerases / metabolism. Protease Inhibitors / pharmacology. Thrombocytopenia / drug therapy. Time Factors

  • Hazardous Substances Data Bank. BORTEZOMIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15609327.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


27. Nonami A, Miyamoto T, Kuroiwa M, Kunisaki Y, Kamezaki K, Takenaka K, Harada N, Teshima T, Harada M, Nagafuji K: Successful treatment of primary plasma cell leukaemia by allogeneic stem cell transplantation from haploidentical sibling. Jpn J Clin Oncol; 2007 Dec;37(12):969-72
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of primary plasma cell leukaemia by allogeneic stem cell transplantation from haploidentical sibling.
  • Primary plasma cell leukaemia (PCL) is a rare, aggressive neoplasm of plasma cell dyscrasia.
  • Here, we describe a 42-year-old man with primary PCL, who was successfully treated with haploidentical (2-HLA loci mismatched) haematopoietic stem-cell transplantation (HSCT).
  • To overcome the human leukocyte antigen (HLA) disparity, in vivo T-cell purging by the pre-transplant administration of antithymocyte globulin followed by a conventional prophylactic treatment against graft-versus-host disease (GVHD) resulted in an avoidance of severe GVHD as well as infectious complications.
  • [MeSH-major] Haplotypes. Hematopoietic Stem Cell Transplantation. Leukemia, Plasma Cell / surgery. Siblings. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Antilymphocyte Serum / administration & dosage. Bone Marrow Purging. Graft vs Host Disease / prevention & control. Humans. Immunosuppressive Agents / administration & dosage. Male. T-Lymphocytes. Transplantation, Homologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18055567.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / Immunosuppressive Agents
  •  go-up   go-down


28. Talamo G, Castellani W, Dolloff NG: Prozone effect of serum IgE levels in a case of plasma cell leukemia. J Hematol Oncol; 2010;3:32
Genetic Alliance. consumer health - Plasma cell leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prozone effect of serum IgE levels in a case of plasma cell leukemia.
  • We describe a case of multiple myeloma (MM) and secondary plasma cell leukemia (PCL) secreting IgE-kappa immunoglobulin.
  • In our patient, the only tumor marker available for monitoring the therapeutic response to chemotherapy and allogeneic stem cell transplantation was the quantitative M component at serum protein electrophoresis (SPEP), because serum free light chains were in the normal range, Bence-Jones proteinuria was absent, and quantitative serum IgE levels provided inaccurate and erratic results, due to the prozone effect.
  • [MeSH-major] Immunoglobulin E / blood. Leukemia, Plasma Cell / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 2000 Oct;46(10):1719-21 [11017960.001]
  • [Cites] Int J Hematol. 2009 Oct;90(3):402-6 [19728026.001]
  • [Cites] Immunology. 1967 Oct;13(4):381-94 [4168094.001]
  • [Cites] Br Med J. 1972 Nov 4;4(5835):250-1 [5083879.001]
  • [Cites] Blut. 1987 Jul;55(1):55-60 [3607296.001]
  • [Cites] Acta Haematol. 1991;85(1):41-4 [2011930.001]
  • [Cites] Clin Chem. 1992 Nov;38(11):2328-32 [1424132.001]
  • [Cites] Am J Hematol. 1994 Mar;45(3):262-4 [8296801.001]
  • [Cites] Scand J Clin Lab Invest. 1999 Oct;59(6):451-6 [10612556.001]
  • [Cites] Int Arch Allergy Immunol. 1997 Apr;112(4):415-21 [9104800.001]
  • [Cites] Eur J Haematol. 2007 Apr;78(4):353-7 [17378894.001]
  • [Cites] Leuk Lymphoma. 2007 Apr;48(4):723-30 [17454630.001]
  • [Cites] Br J Haematol. 2007 Jul;138(2):176-85 [17593024.001]
  • [Cites] Transfusion. 2008 Oct;48(10):2056 [18928508.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):637-8 [19064952.001]
  • [Cites] Leukemia. 2009 Feb;23(2):215-24 [19020545.001]
  • [Cites] Int J Hematol. 2009 Apr;89(3):259-68 [19326058.001]
  • [Cites] J Zhejiang Univ Sci B. 2009 Jul;10(7):559-62 [19585675.001]
  • [Cites] Pathology. 2010 Jan;42(1):82-4 [20025486.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1570-1 [12393502.001]
  • (PMID = 20828419.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 37341-29-0 / Immunoglobulin E
  • [Other-IDs] NLM/ PMC2944146
  •  go-up   go-down


29. Xu W, Li JY, Fan L, Chen LJ, Qiu HR, Qiu HX, Lu H: Molecular cytogenetic aberrations in 21 Chinese patients with plasma cell leukemia. Int J Lab Hematol; 2009 Jun;31(3):338-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular cytogenetic aberrations in 21 Chinese patients with plasma cell leukemia.
  • Plasma cell leukemia (PCL) is a rare malignant plasma cell disorder.
  • Cytogenetic studies performed on plasma cell disorders are scarce and difficult because of the low proliferation rate of plasma cells (PCs).
  • Among 21 PCL patients, molecular cytogenetic aberrations were found in 18 (81.8%) patients, four (19.0%) patients simultaneously had 13q14 deletion, illegitimate IgH translocation and 1q abnormality.
  • Chromosome 1 abnormality was found in seven (33.3%) patients, one with deletion of 1q, six with at least three copies amplifications of 1q12 (Amp1q12).
  • It was showed that most PCL had chromosomal abnormalities, 14q32 rearrangement, 13q14 deletion and chromosome 1 abnormality are the frequent abnormalities, and over half of the 14q32 rearrangement were t(11;14) or t(4;14).
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 13 / genetics. Chromosomes, Human, Pair 14 / genetics. Leukemia, Plasma Cell / genetics

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18284415.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


30. Masuda M, Inoue Y, Tanosaki R, Kanzaki S, Ogawa K: Development of solitary plasmacytoma in the internal auditory canal and inner ear after allogeneic hematopoietic stem cell transplantation for plasma cell leukemia. Jpn J Clin Oncol; 2007 Sep;37(9):701-3
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of solitary plasmacytoma in the internal auditory canal and inner ear after allogeneic hematopoietic stem cell transplantation for plasma cell leukemia.
  • Here we report the first case of the development of intracranial solitary plasmacytoma in the inner ear after allogeneic stem cell transplantation (allo-SCT) in a 39-year-old Japanese female with primary plasma cell leukemia (PCL).
  • She was successfully treated with local irradiation and survived more than 6 years from the time of diagnosis and transplantation.
  • This case elucidates the biology of PCL and stresses the need for an individual approach to the clinical management of patients with plasma cell neoplasm undergoing allo-SCT.
  • [MeSH-major] Ear Neoplasms / etiology. Ear, Inner. Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Plasma Cell / surgery. Plasmacytoma / etiology

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17673474.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


31. Katodritou E, Verrou E, Gastari V, Hadjiaggelidou C, Terpos E, Zervas K: Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? Leuk Res; 2008 Jul;32(7):1153-6
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?
  • Plasma cell leukemia (PCL) is a rare and aggressive form of plasma cell dyscrasias.
  • Its special biological characteristics may play an important role in the poor outcome when treated with conventional therapy or even with stem cell transplantation.
  • New treatment approaches based on the biology of this disease are mandatory.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Dexamethasone / therapeutic use. Leukemia, Plasma Cell / drug therapy. Pyrazines / therapeutic use

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18083228.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


32. Chang H, Qi X, Yeung J, Reece D, Xu W, Patterson B: Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res; 2009 Feb;33(2):259-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia.
  • Plasma cell leukemia (PCL) is a rare form of plasma cell malignancy, few large series reported underlying genetic abnormalities.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 1. Leukemia, Plasma Cell / genetics. Leukemia, Plasma Cell / pathology

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Genetics Home Reference. consumer health - chromosome 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18676019.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


33. Pérez-Andrés M, Almeida J, Martín-Ayuso M, Moro MJ, Martín-Nuñez G, Galende J, Borrego D, Rodríguez MJ, Ortega F, Hernandez J, Moreno I, Domínguez M, Mateo G, San Miguel JF, Orfao A, Spanish Network on multiple myeloma (G03/136), Spanish Network of Cancer Research Centers (C03/10): Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia; 2005 Mar;19(3):449-55
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment.
  • The immunological bone marrow (BM) microenvironment plays a major role in controlling growth and survival of clonal plasma cells (PC); this might translate into different patterns of expression of molecules involved in immune responses on PC from different types of monoclonal gammopathies (MG).
  • We have studied the expression of a group of nine such molecules on both BMPC and the plasma of 61 newly diagnosed MG patients (30 MG of undetermined significance (MGUS), 27 multiple myeloma (MM) and four plasma cell leukemia (PCL)) and five normal individuals.
  • [MeSH-major] Antigens, CD / genetics. Bone Marrow / pathology. Leukemia, Plasma Cell / genetics. Multiple Myeloma / genetics. Paraproteinemias / immunology. Plasma Cells / immunology
  • [MeSH-minor] Aged. Clone Cells / immunology. Female. Gene Expression Profiling / methods. Humans. Immunophenotyping / methods. Male

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15674420.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


34. Chan SM, George T, Cherry AM, Medeiros BC: Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report. Cases J; 2009;2(1):121
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report.
  • BACKGROUND: Plasma cell leukemia (PCL) is a rare lymphoproliferative disorder considered to be a variant of multiple myeloma.
  • It is an aggressive disease with a poor clinical response to standard chemotherapeutic agents.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 2008 Jul;32(7):1153-6 [18083228.001]
  • [Cites] Leukemia. 2008 May;22(5):1044-52 [18216867.001]
  • [Cites] J Clin Pathol. 2008 Jul;61(7):832-6 [18077770.001]
  • [Cites] Leuk Lymphoma. 2008 Oct;49(10):2012-4 [18720213.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2377-80 [12424198.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3892-901 [17679727.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3380-1 [17664489.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2285-90 [17469169.001]
  • [Cites] Blood. 2002 May 15;99(10):3735-41 [11986230.001]
  • [Cites] Br J Haematol. 2008 May;141(4):512-6 [18371113.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1588-94 [12730120.001]
  • [Cites] Lancet. 2004 Mar 13;363(9412):875-87 [15031034.001]
  • [Cites] Int J Cancer. 2005 Apr 20;114(4):665-7 [15609327.001]
  • [Cites] Clin Adv Hematol Oncol. 2003 Oct;1(10):596-600 [16258456.001]
  • [Cites] Ann Hematol. 2006 Apr;85(4):263-7 [16416115.001]
  • [Cites] Blood. 2006 May 1;107(9):3492-4 [16410442.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3113-20 [16754936.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1467-73 [16855634.001]
  • [Cites] Int J Hematol. 2006 Dec;84(5):406-12 [17189220.001]
  • [Cites] Onkologie. 2007 Apr;30(4):193-5 [17396042.001]
  • (PMID = 19192311.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2644294
  •  go-up   go-down


35. Brück P, Mousset S, Bühme A, Hoelzer D, Atta J: Nonsecretory primary plasma cell leukemia with good response to thalidomide-based treatment. Int J Hematol; 2007 Jul;86(1):66-8
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonsecretory primary plasma cell leukemia with good response to thalidomide-based treatment.
  • Primary plasma cell leukemia (PCL) is a rare hematologic disorder with distinct features.
  • The criterion for the diagnosis of PCL is based on the finding of malignant plasma cells in the peripheral blood (more than 2 x 10(9)/L or more than 20% of white blood cells).
  • Examination of blood smears led to the diagnosis of PCL, which was confirmed by bone marrow biopsy.
  • After an oral induction chemotherapy consisting of cyclophosphamide and high dose dexamethasone followed by one cycle of high-dose dexamethasone and thalidomide no evidence of the disease in the peripheral blood was detectable.
  • Six months after first diagnosis, the patient was found to have bone marrow and peripheral blood relapse with anemia and neutropenia in the clinical context of acute on chronic renal failure.
  • After a limited response to further chemotherapy, the patient died 14 months after the first diagnosis while on dexamethasone maintenance.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Plasma Cell / drug therapy. Thalidomide / therapeutic use

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17675269.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


36. Marionneaux S, Monsalve B, Plante N, Shulman S, Vega AM: The application of Beckman Coulter VCS technology at a major cancer center, with emphasis on the detection of circulating immature plasma cells in plasma cell leukemia. Lab Hematol; 2006;12(4):210-6
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The application of Beckman Coulter VCS technology at a major cancer center, with emphasis on the detection of circulating immature plasma cells in plasma cell leukemia.
  • Circulating plasma cells are not a common finding in multiple myeloma.
  • Being able to detect plasma cells in peripheral blood is important because they are a prognostic indicator that correlates with disease progression.
  • Furthermore, the peripheral blood plasma cell population can demonstrate morphologic variability.
  • Immature plasma cells, both plasmablasts and proplasmacytes are associated with more aggressive disease and shortened survival.
  • We encountered 3 multiple myeloma patients with circulating immature plasma cells that appeared as distinct populations on our hematology analyzer's automated white blood cell (WBC) differential.
  • The immature plasma cells, given their unique cellular characteristics, appeared in a common place within the WBC differential scatterplot in each patient.
  • In our laboratory, we have utilized this common graphic pattern to screen for immature plasma cells.
  • We have also used examination of the scatterplots in other hematologic malignancies such as chronic lymphocytic leukemia.
  • [MeSH-major] Data Display. Flow Cytometry / instrumentation. Leukemia, Plasma Cell / diagnosis. Leukocyte Count / instrumentation. Multiple Myeloma / immunology. Plasma Cells / classification

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17118772.001).
  • [ISSN] 1080-2924
  • [Journal-full-title] Laboratory hematology : official publication of the International Society for Laboratory Hematology
  • [ISO-abbreviation] Lab Hematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Wandroo FA, Mahendra P, Khuroo RA, Neilson J: Plasma cell leukaemia presenting with polyarthralgia and phalangeal lytic lesions. Clin Lab Haematol; 2005 Jun;27(3):203-5
MedlinePlus Health Information. consumer health - Foot Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukaemia presenting with polyarthralgia and phalangeal lytic lesions.
  • The patient was subsequently diagnosed to have plasma cell leukaemia.
  • The most common sites of bony involvement in plasma cell dyscrasia are skull, vertebrae, ribs and long bones.
  • Although it is quite unusual for plasma cell leukaemia or myeloma to involve solely small joints of hands and feet, we suggest plasma cell dyscrasia should be kept in the differential diagnostic list for polyarthralgia in adults if usual causes are ruled out.
  • [MeSH-major] Arthralgia / complications. Fingers / pathology. Foot / pathology. Leukemia, Plasma Cell / complications. Osteolysis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15938728.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


38. Khosravi Shahi P: [Plasma cell leukaemia: a rare variant of multiple myeloma. A case report]. An Med Interna; 2005 Nov;22(11):532-4
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Plasma cell leukaemia: a rare variant of multiple myeloma. A case report].
  • [Transliterated title] Leucemia de células plasmáticas: variante rara del mieloma múltiple. Caso clínico.
  • Plasma cell leukaemia is a rare variant of multiple myeloma (2-3%), with an aggressive disease with short survival.
  • It is defined as circulating peripheral blood plasma cells exceeding 2.000/ul and 20% of peripheral blood white cells.
  • We present the case of 32-years-old man with left chest-wall pain, hepatomegaly, righ cervical adenopathy, 8800 leukocytes/ul with 33% of lymphocytes and 40% of plasma cell, 10.8 g/dl of proteins and a monoclonal hypergammaglobulinemia.
  • Bone marrow biopsy showed 40-50 % of intramedullary plasma cell.
  • [MeSH-major] Leukemia, Plasma Cell / diagnosis. Multiple Myeloma / diagnosis

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454587.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


39. Chang H, Yeung J, Xu W, Ning Y, Patterson B: Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation. Br J Haematol; 2006 Sep;134(6):613-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation.
  • The genetic events that lead to tumour progression in plasma cell dyscrasia are not well understood.
  • Interphase cytoplasmic fluorescence in situ hybridisation was used to investigate the CKS1B amplification status (at 1q21) in clonal plasma cells from 123 patients: 23 monoclonal gammopathy of undetermined significance (MGUS), 75 multiple myeloma (MM) and 26 plasma cell leukaemia (PCL).
  • [MeSH-major] Carrier Proteins / genetics. Cyclin-Dependent Kinases / genetics. Gene Amplification. Leukemia, Plasma Cell / genetics. Monoclonal Gammopathy of Undetermined Significance / genetics. Multiple Myeloma / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CDC2-CDC28 Kinases. Chi-Square Distribution. Disease Progression. Female. Humans. In Situ Hybridization, Fluorescence. Interphase. Male. Middle Aged

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889615.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CKS1B protein, human; 0 / Carrier Proteins; EC 2.7.11.22 / CDC2-CDC28 Kinases; EC 2.7.11.22 / Cyclin-Dependent Kinases
  •  go-up   go-down


40. Alexandrescu DT, Koulova L, Wiernik PH: Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide: a case report and review of the literature. Clin Exp Dermatol; 2005 Jul;30(4):391-4
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide: a case report and review of the literature.
  • We report the case of a 54-year-old African-American male with IgG multiple myeloma (MM) with disease resistant to multiple chemotherapy regimens and immunomodulatory treatment with thalidomide.
  • In spite of achieving a partial remission of short duration, his disease accelerated to peripheral plasmacytosis and subsequent development of cutaneous plasmacytomas.
  • The malignant plasma cells derived from the dermal lesions were CD45+, CD38+, CD138+ and matched the immunophenotype of the plasmacytes during the leukaemic phase.
  • We discuss the possible relationship between the patient's unusual disease course and the administered chemo- and immunotherapy.
  • [MeSH-major] Immunosuppressive Agents / adverse effects. Leukemia, Plasma Cell / pathology. Leukemic Infiltration / chemically induced. Multiple Myeloma / drug therapy. Skin / pathology. Thalidomide / adverse effects

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15953079.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 4Z8R6ORS6L / Thalidomide
  • [Number-of-references] 10
  •  go-up   go-down


41. Krüger WH, Kiefer T, Schüler F, Lotze C, Busemann C, Dölken G: Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation. Onkologie; 2007 Apr;30(4):193-5
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation.
  • BACKGROUND: Chromosomal deletion of q13 (del q13) and plasma cell leukemia predict both a worse prognosis in myeloma.
  • Experiences with bortezomib in plasma cell leukemia prior to allogeneic stem cell transplantation (SCT) have not yet been reported.
  • The myeloma progressed to plasma cell leukemia.
  • Bortezomib was given, free light chain (FLC) excretion decreased, and myeloma cells disappeared from blood and decreased in marrow.
  • CONCLUSION: This case gives evidence for an excellent initial response of plasma cell leukemia to bortezomib, however, early relapse after SCT clearly indicates limitations of both bortezomib therapy and allogeneic SCT in high-risk myeloma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Boronic Acids / administration & dosage. Hematopoietic Stem Cell Transplantation. Leukemia, Plasma Cell / drug therapy. Multiple Myeloma / drug therapy. Pyrazines / administration & dosage

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17396042.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Immunoglobulin A; 0 / Immunoglobulin Light Chains; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


42. Tageja N, Nagi J, Valent J, Zonder J: Plasma cell leukemia presenting as organizing pneumonia refractory to high-dose steroid therapy. South Med J; 2010 Jul;103(7):706-10
Genetic Alliance. consumer health - Plasma cell leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukemia presenting as organizing pneumonia refractory to high-dose steroid therapy.
  • A case of steroid-refractory organizing pneumonia (OP) as the initial presentation of plasma cell leukemia (PCL) in a patient who had no prior exposure to chemotherapy or radiation is described.
  • Since OP is traditionally a steroid-responsive disease, this case raises the possibility of a previously unknown patient subgroup with variable disease pattern and/or behavior in patients with plasma cell neoplasm.
  • [MeSH-major] Cryptogenic Organizing Pneumonia / diagnosis. Leukemia, Plasma Cell / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Female. Glucocorticoids / therapeutic use. Humans. Lung / pathology. Middle Aged. Multiple Myeloma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20531051.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids
  •  go-up   go-down


43. Ishigaki T, Sasaki K, Watanabe K, Nakamura N, Toyota S, Kobayashi H, Tohda S: Amplification of IGH/CCND1 fusion gene in a primary plasma cell leukemia case. Cancer Genet Cytogenet; 2010 Aug;201(1):62-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amplification of IGH/CCND1 fusion gene in a primary plasma cell leukemia case.
  • The IGH/CCND1 fusion gene has been reported in many hematologic tumors such as mantle cell lymphoma, chronic lymphocytic leukemia, prolymphocytic leukemia, multiple myeloma, and plasma cell leukemia.
  • We report a case of plasma cell leukemia showing five IGH/CCND1 fusion signals by interphase fluorescence in situ hybridization (FISH).
  • The amplification of the IGH/CCND1 fusion gene may contribute to the aggressive course of the disease.
  • To our knowledge, this is the first case showing amplification of the IGH/CCND1 gene in plasma cell neoplasms.
  • [MeSH-major] Cyclin D1 / genetics. Immunoglobulin Heavy Chains / genetics. Leukemia, Plasma Cell / genetics

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20633772.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / Immunoglobulin Heavy Chains; 136601-57-5 / Cyclin D1
  •  go-up   go-down


44. Kalyani R, Kumar ML: Plasma cell leukemia presenting as acute renal failure: a case report. Indian J Pathol Microbiol; 2007 Jan;50(1):86-8
Genetic Alliance. consumer health - Plasma cell leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukemia presenting as acute renal failure: a case report.
  • Plasma cell leukemia is a rare form of malignant plasma cell dyscrasia.
  • A case of primary plasma cell leukemia presenting as acute renal failure is reported here.
  • [MeSH-major] Acute Kidney Injury / etiology. Leukemia, Plasma Cell / complications. Leukemia, Plasma Cell / diagnosis
  • [MeSH-minor] Blood Cells / cytology. Blood Proteins / analysis. Humans. Male. Middle Aged. Skull / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17474270.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Blood Proteins
  •  go-up   go-down


45. Hirase N, Muta S, Abe Y, Muta K: [Plasma cell leukemia presenting with cleaved nuclei and a monocytoid appearance]. Rinsho Ketsueki; 2007 Jan;48(1):64-6
Genetic Alliance. consumer health - Plasma cell leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Plasma cell leukemia presenting with cleaved nuclei and a monocytoid appearance].
  • A 74-year-old man presented with anemia, thrombocytopenia and leukocytosis with 41% abnormal cells having cleaved and monocytoid nuclei.
  • The bone marrow was infiltrated with 43.6% abnormal cells that were negative for peroxidase staining and positive for PAS staining.
  • Immunostaining also revealed expression of IgA and kappa-type in the abnormal cells.
  • The patient was diagnosed as having plasma cell leukemia but the morphological findings were unusual.
  • This case suggests that immunostaining of abnormal cells is required for the differential diagnosis of plasma cell leukemia in leukocytosis.
  • [MeSH-major] Cell Nucleus / pathology. Leukemia, Plasma Cell / pathology
  • [MeSH-minor] Aged. Antigens, CD38 / biosynthesis. Diagnosis, Differential. Humans. Leukocytosis / pathology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313079.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


46. Nakaya A, Ogihara T, Awaya N: Plasma cell leukemia presenting with diplopia due to unilateral abducens paralysis and complex chromosomal abnormalities. Intern Med; 2006;45(9):637-40
MedlinePlus Health Information. consumer health - Paralysis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukemia presenting with diplopia due to unilateral abducens paralysis and complex chromosomal abnormalities.
  • Involvement of cranial nerves is rare in plasma cell leukemia (PCL).
  • Although the patient showed an initial response to chemotherapy, he died of disease progression 5 months later.
  • [MeSH-major] Abducens Nerve Diseases / complications. Chromosome Aberrations. Diplopia / etiology. Leukemia, Plasma Cell / complications. Leukemia, Plasma Cell / genetics. Paralysis / complications
  • [MeSH-minor] Aged. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 14. Disease Progression. Fatal Outcome. Humans. Liver / radiography. Magnetic Resonance Imaging. Male. Sphenoid Sinus / pathology. Tomography, X-Ray Computed. Translocation, Genetic

  • Genetic Alliance. consumer health - paralysis.
  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755096.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


47. Ballanti S, Mastrodicasa E, Bolli N, Lotti F, Capolsini I, Berchicci L, Merigiola C, Giordano G, Tabilio A: Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia. Nat Clin Pract Oncol; 2007 Dec;4(12):722-5
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.
  • BACKGROUND: A 68-year-old man diagnosed with primary plasma-cell leukemia was given thalidomide maintenance treatment for his disease.
  • DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.
  • [MeSH-major] Angiogenesis Inhibitors / adverse effects. Leukemia, Plasma Cell / drug therapy. Tachycardia, Ventricular / chemically induced. Thalidomide / adverse effects

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18037876.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


48. Lommatzsch SE, Bellizzi AM, Cathro HP, Rosner MH: Acute renal failure caused by renal infiltration by hematolymphoid malignancy. Ann Diagn Pathol; 2006 Aug;10(4):230-4
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the second case, infiltration of the kidneys by plasma cell leukemia resulted in dialysis dependence.
  • To our knowledge, this represents the first reported case of ARF attributable to documented renal infiltration by plasma cell leukemia.
  • A review of the potential causes of renal failure in hematolymphoid malignancy, focusing on the direct impact of the infiltrative process and on the spectrum of renal disease in plasma cell dyscrasia, is presented.
  • [MeSH-major] Acute Kidney Injury / etiology. Kidney / pathology. Leukemia, Plasma Cell / complications. Leukemic Infiltration. Lymphoma, Non-Hodgkin / complications

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Allopurinol .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844565.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites; 4Z8R6ORS6L / Thalidomide; 63CZ7GJN5I / Allopurinol; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


49. Sáez B, Martín-Subero JI, Lahortiga I, Largo C, Larrayoz MJ, Odero MD, Prosper F, Cigudosa JC, Siebert R, Calasanz MJ: Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes. Cancer Genet Cytogenet; 2007 May;175(1):65-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate this hypothesis, we have characterized the plasma cell leukemia cell line SK-MM2 and a primary myeloma both carrying simultaneous IGH-FGFR3/MMSET and IGH-CCND1 fusions as shown by multicolor fluorescence in situ hybridization.
  • Thus, biallelic IGH translocations might exert different pathogenetic effects in plasma cell disorders.
  • [MeSH-minor] Alleles. Cell Line. Chromosome Banding. Chromosome Painting. Cyclin D. Gene Expression Regulation, Neoplastic. Humans. Karyotyping. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498561.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin D; 0 / Cyclins; 0 / Immunoglobulin Heavy Chains; 0 / RNA, Messenger; 0 / Repressor Proteins; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.1.1.43 / WHSC1 protein, human; EC 2.7.10.1 / FGFR3 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3
  •  go-up   go-down


50. Funes C, Garcia-Candel F, Majado MJ, González-García C, Bas A, Salido E, Moraleda JM, Morales A: Splenic rupture in a plasma cell leukemia, mobilized with G-CSF for autologous stem cell transplant. J Clin Apher; 2010;25(4):223-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic rupture in a plasma cell leukemia, mobilized with G-CSF for autologous stem cell transplant.
  • Splenic rupture (SR) is a rare adverse event observed in patients treated with G-CSF as a peripheral hematopoietic stem cell (PHSC) mobilizing agent, mostly in myeloma multiple and amiloidosis; to date, to our knowledge, it has not been previously described in plasma-cell leukemia (PCL).
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / adverse effects. Leukemia, Plasma Cell / complications. Splenic Rupture / etiology
  • [MeSH-minor] Fatal Outcome. Female. Hematopoietic Stem Cell Mobilization / methods. Hematopoietic Stem Cell Transplantation / methods. Humans. Middle Aged. Splenomegaly / chemically induced. Transplantation, Autologous

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20818717.001).
  • [ISSN] 1098-1101
  • [Journal-full-title] Journal of clinical apheresis
  • [ISO-abbreviation] J Clin Apher
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


51. Delhommeau F, Huguet S, Gachet J, van den Akker J, Lagrange M: Primary plasma cell leukemia mimicking an adult T-cell leukemia-lymphoma: a case report. Acta Cytol; 2010 Mar-Apr;54(2):187-9
Genetic Alliance. consumer health - Plasma cell leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary plasma cell leukemia mimicking an adult T-cell leukemia-lymphoma: a case report.
  • BACKGROUND: Malignant plasma cells ofmultiple myeloma (MM), or plasma cell leukemia (PCL), may present highly variable morphologic aspects.
  • Adult T-cell leukemia-lymphoma (ATLL) is a peripheral T-cell neoplasm composed of highly pleomorphic lymphoid cells.
  • We report an unusual case ofprimary PCL with misleading cellular morphology and some clinical and biologic similarities simulating ATLL.
  • Blood cell count showed anemia and thrombocytopenia and a hyperleukocytosis composed of deeply basophilic cells with a polylobulated nucleus resembling flower cells.
  • An ATLL diagnosis was given at first, without ruling out the possibility of a PCL diagnosis.
  • Immunophenotyping was key to the diagnosis of primary PCL.
  • CONCLUSION: Some clinical and biological overlap may exist between PCL and ATLL, leading to a false diagnosis or delaying a correct one.
  • An accurate cytologic analysis leading to a rapid detection of plasma cell markers is essential for an early diagnosis.
  • [MeSH-major] Leukemia, Plasma Cell / diagnosis. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Plasma Cells / pathology
  • [MeSH-minor] Adult. Antigens, CD38 / analysis. Diagnosis, Differential. Humans. Male. Syndecan-1 / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20391976.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Syndecan-1; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


52. de Larrea CF, Cibeira MT, Vallansot R, Colomo L, Bladé J: Increased serum tumor markers (CA125 and CA15.3) in primary plasma cell leukemia: a case report and review of the literature. Clin Lymphoma Myeloma; 2008 Oct;8(5):312-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased serum tumor markers (CA125 and CA15.3) in primary plasma cell leukemia: a case report and review of the literature.
  • 73-year-old woman complaining of bone pain and weight loss was suspected to have a malignant disease, and extensive laboratory investigations were carried out.
  • She was diagnosed with multiple myeloma; however, because of the finding of extremely high serum levels of CA125 and CA15.3 and focal liver lesions, a concomitant solid tumor was suspected, which was then excluded with the appropriate tests, including an ultrasound-guided liver biopsy.
  • While being diagnosed, the patient developed a rapidly evolving plasma cell leukemia with a simultaneous increase in CA125 and CA15.3.
  • After treatment with cyclophosphamide and dexamethasone, the peripheral blood plasma cells disappeared and there was a dramatic decrease in the CA125 and CA15.3 tumor markers.
  • High levels of the latter can be observed in patients with aggressive plasma cell dyscrasias, an observation that is crucial in order to avoid unnecessary tests that can result in treatment delay.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Leukemia, Plasma Cell / blood. Mucin-1 / blood

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18854288.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Mucin-1; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


53. Du S, Rashidi HH, Le DT, Kipps TJ, Broome HE, Wang HY: Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma. Int J Clin Exp Pathol; 2010;3(4):448-57
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma.
  • Systemic mastocytosis with associated clonal haematological non-mast cell lineage disease (SM-AHNMD) is a heterogeneous group of mast cell disorders with different clinical, pathologic and underlying molecular characteristics.
  • Here we report two cases of SM-AHNMD, in which the AHNMD component is chronic lymphocytic leukemia in one case, and concurrent chronic lymphocytic leukemia as well as plasma cell myeloma in another case.
  • To the best of our knowledge, this is the first case report of SM-AHNMD with chronic lymphocytic leukemia and plasma cell dyscrasia simultaneously.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / complications. Mastocytosis / complications. Multiple Myeloma / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Separation. DNA Mutational Analysis. Female. Flow Cytometry. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged. Proto-Oncogene Proteins c-kit / genetics

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Mast cell disease.
  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Genetic Alliance. consumer health - Systemic mastocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2009 Oct 29;114(18):3769-72 [19713463.001]
  • [Cites] J Pathol. 2010 Apr;220(5):586-95 [20112369.001]
  • [Cites] Histopathology. 2001 Aug;39(2):150-5 [11493331.001]
  • [Cites] Haematologica. 2001 Oct;86(10):1106-7 [11602421.001]
  • [Cites] Clin Rev Allergy Immunol. 2002 Apr;22(2):107-18 [11975418.001]
  • [Cites] Leuk Res. 2003 Aug;27(8):739-42 [12801532.001]
  • [Cites] J Clin Pathol. 2003 Aug;56(8):575-8 [12890804.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):801-5 [15160959.001]
  • [Cites] J Clin Pathol. 2004 Jun;57(6):604-8 [15166264.001]
  • [Cites] Cancer. 1988 Sep 1;62(5):965-72 [3409177.001]
  • [Cites] Ann Hematol. 1998 Mar-Apr;76(3-4):167-74 [9619735.001]
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):35-48 [15621779.001]
  • [Cites] J Clin Pathol. 2006 Mar;59(3):264-8 [16505276.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 May;6(6):478-83 [16796779.001]
  • [Cites] Ann Oncol. 2006 Aug;17(8):1275-82 [16788002.001]
  • [Cites] J Clin Pathol. 2006 Aug;59(8):875-8 [16873565.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2366-72 [16741248.001]
  • [Cites] Leuk Res. 2007 Dec;31(12):1755-8 [17521719.001]
  • [Cites] Leuk Res. 2008 Jul;32(7):1160-3 [18061667.001]
  • [Cites] Hum Pathol. 2008 Jun;39(6):917-24 [18448146.001]
  • [Cites] Leuk Res. 2009 Jun;33(6):856-9 [19147227.001]
  • [Cites] Mod Pathol. 2009 Jun;22(6):807-16 [19287458.001]
  • [Cites] Am J Clin Pathol. 2009 Sep;132(3):438-47 [19687320.001]
  • [Cites] Am J Hematol. 2009 Dec;84(12):790-4 [19890907.001]
  • [Cites] Leuk Res. 2001 Jul;25(7):563-70 [11377681.001]
  • (PMID = 20490336.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC2872752
  • [Keywords] NOTNLM ; Chronic lymphocytic leukemia / systemic mastocytosis / systemic mastocytosis with associated clonal haematological non-mast cell lineage disease
  •  go-up   go-down


54. Hosono N, Yamauchi T, Nakamura T, Yamashita T, Ueda T: [Plasma cell leukemia induced to complete remission with negative minimal residual disease by qualitative PCR analysis after hyper-CVAD and high-dose melphalan followed by autologous peripheral blood stem cell transplantation]. Gan To Kagaku Ryoho; 2008 Mar;35(3):533-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Plasma cell leukemia induced to complete remission with negative minimal residual disease by qualitative PCR analysis after hyper-CVAD and high-dose melphalan followed by autologous peripheral blood stem cell transplantation].
  • A 69-year-old Japanese man was diagnosed as having primary plasma cell leukemia.
  • His malignant plasma cells had a chromosomal translocation t(11;14)(q13;q32) that created overexpression of cyclin D1.
  • Thereafter, the patient received high-dose melphalan (125 mg/m(2)) followed by autologous peripheral blood stem cell transplantation.
  • Despite complete cytogenetic remission, the disease relapsed 6 months later, and the patient eventually died 16 months following the diagnosis.
  • Plasma cell leukemia is a rare hematological malignancy with a poor prognosis.
  • The present case suggested the effectiveness of the combination of hyper-CVAD and high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Plasma Cell / drug therapy. Leukemia, Plasma Cell / surgery. Melphalan / therapeutic use. Peripheral Blood Stem Cell Transplantation

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347412.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan; CVAD protocol
  •  go-up   go-down


55. Iino M, Nakajima A, Shindo H: [Long-term complete remission in primary plasma cell leukemia after treatment with VAD chemotherapy and tandem autologous peripheral blood stem cell transplantation]. Gan To Kagaku Ryoho; 2008 Dec;35(13):2441-3
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term complete remission in primary plasma cell leukemia after treatment with VAD chemotherapy and tandem autologous peripheral blood stem cell transplantation].
  • Through hematologic and bone marrow examination, we diagnosed her illness as primary plasma cell leukemia.
  • Afterward, the patient received high-dose cyclophosphamide (4 g/m(2))for hematopoietic stem cell mobilization, and peripheral blood hematopoietic stem cells were collected 14 days later from the start of chemotherapy.
  • Thereafter, the patient received 2 courses of high-dose melphalan (200 mg/m(2)), followed by tandem autologous peripheral blood stem cell transplantation.
  • Taken together, although primary plasma cell leukemia is a rare hematologic malignancy with poor prognosis, the intensive chemotherapy followed by tandem autologous peripheral blood stem cell transplantation may well improve the clinical outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Plasma Cell / drug therapy. Leukemia, Plasma Cell / surgery. Peripheral Blood Stem Cell Transplantation

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19098420.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; VAD combination
  •  go-up   go-down


56. Sondes M, Choumous K, Moez E, Naourez A, Fatma BS, Faiza M, Taoufik S: [Secondary plasma cell leukemia. Report of 2 cases]. Tunis Med; 2005 Jul;83(7):433-6
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Secondary plasma cell leukemia. Report of 2 cases].
  • [Transliterated title] La leucemie a plasmocytes secondaire: a propos de deux cas.
  • Plasma cell leukemia is considered as the leukemic variant of multiple myeloma.
  • There are two forms: a secondary one following a known myeloma, the diagnosis of which is easy, and a primary one arising without a preceding phase of multiple myeloma.
  • The diagnosis of the latter form is more difficult, a differential diagnosis has often to be discussed with other lymphoproliferative diseases.
  • We report 2 cases of secondary plasma cell leukemia diagnosed over ten years, among 59 of multiple myeloma cases.
  • [MeSH-major] Leukemia, Plasma Cell / etiology. Multiple Myeloma / pathology

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16220704.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


57. Fianchi L, Montini L, Caira M, Voso MT, Maviglia R, Posteraro B, Pagano L: Combined voriconazole plus caspofungin therapy for the treatment of probable Geotrichum pneumonia in a leukemia patient. Infection; 2008 Feb;36(1):65-7
Hazardous Substances Data Bank. CASPOFUNGIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined voriconazole plus caspofungin therapy for the treatment of probable Geotrichum pneumonia in a leukemia patient.
  • Infections by Geotrichum capitatum, occurring in leukemia patients, are rarely reported and generally are characterized by a poor prognosis.
  • Here we reported a case of G. capitatum pneumonia in a patient with plasma cell leukemia, successfully treated with antifungal combination with voriconazole and caspofungin and supportive therapy.
  • [MeSH-minor] Aged. Drug Therapy, Combination. Female. Geotrichum. Humans. Immunocompromised Host. Leukemia, Plasma Cell / complications. Leukemia, Plasma Cell / drug therapy. Voriconazole

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17926005.001).
  • [ISSN] 0300-8126
  • [Journal-full-title] Infection
  • [ISO-abbreviation] Infection
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Pyrimidines; 0 / Triazoles; F0XDI6ZL63 / caspofungin; JFU09I87TR / Voriconazole
  •  go-up   go-down


58. Hasmoni MH, Wahid FA, Keng CS: Primary plasma cell leukemia presented as progressive paraplegia: a case report. South Med J; 2009 Jan;102(1):101-3
Genetic Alliance. consumer health - Plasma cell leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary plasma cell leukemia presented as progressive paraplegia: a case report.
  • Plasma cell leukemia (PCL) is a rare plasma cell disorder.
  • A 52-year-old man with an atypical presentation of primary plasma cell leukemia is reported.
  • Atypical cells expressed surface and cytoplasmic lambda light chain on immunochemical studies, surface CD45 and CD38.
  • [MeSH-major] Leukemia, Plasma Cell / complications. Paraplegia / etiology. Spinal Cord Compression / etiology
  • [MeSH-minor] Disease Progression. Humans. Magnetic Resonance Imaging. Male. Middle Aged

  • Genetic Alliance. consumer health - Paraplegia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077786.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Bang HI, Yoo JY, Kim KH, Park R, Shin JW, Choi TY, Lee SC, Park HS, Won JH: [A case of central nervous system myelomatosis with complex chromosome aberrations]. Korean J Lab Med; 2010 Aug;30(4):334-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plasma cells were found in the cerebrospinal fluid (CSF), and CSF immunoelectrophoresis revealed abnormal precipitin arcs against anti-IgG and anti-lambda antisera.
  • She was given systemic chemotherapy and eight courses of intrathecal chemotherapy, which cleared plasma cells in the CSF.
  • Two months later, she was given autologous stem cell transplantation.
  • Three months after stem cell transplantation, central nervous system myelomatosis progressed to plasma cell leukemia and two months later, the patient expired.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Chromosome Deletion. Multiple Myeloma / diagnosis. Translocation, Genetic
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cerebrospinal Fluid / cytology. Combined Modality Therapy. Disease Progression. Female. Gene Deletion. Humans. Immunoelectrophoresis. In Situ Hybridization, Fluorescence. Leukemia, Plasma Cell / diagnosis. Middle Aged. Plasma Cells / pathology. Precipitins / metabolism. Receptor, Fibroblast Growth Factor, Type 3 / genetics. Stem Cell Transplantation. Transplantation, Autologous. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20805703.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Precipitins; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / FGFR3 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3
  •  go-up   go-down


60. Usha, Agarwal N, Kumar P, Rai M, Singh RG, Seth M, Saraf SK: Myeloma in young age. Indian J Pathol Microbiol; 2005 Jul;48(3):314-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One case presented with bleeding gum, malena and hepatosplenomegaly and was diagnosed as plasma cell leukemia.

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16761740.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Immunoglobulin G; 9006-99-9 / Bence Jones Protein
  •  go-up   go-down


61. Alatoom A, Elsabrouty R, Willis J, Boils C, Sarode R, Hashim I, Wang HY: Fatal cerebral hemorrhage in a patient with CD19-positive IgM-producing aggressive plasma cell myeloma, hyperviscosity syndrome and cryoglobulinemia. Int J Clin Exp Pathol; 2009;2(5):498-507

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal cerebral hemorrhage in a patient with CD19-positive IgM-producing aggressive plasma cell myeloma, hyperviscosity syndrome and cryoglobulinemia.
  • IgM plasma cell myeloma (PCM) is a rare entity, and CD19 positivity is found in only 1-4% of PCM.
  • Here we report a unique case of IgM PCM, in which the plasma cells are positive for CD19.
  • Despite chemotherapy, the PCM persisted and progressed to plasma cell leukemia, and the patient died of a left frontal hematoma with widespread cerebral hemorrhage extending from left lateral ventricle, third ventricle, fourth ventricle, to cisterna magna.
  • This case represents the first CD19+ IgM-producing PCM and the second case of brain hemorrhage due to plasma cell myeloma/leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2008 Aug;67(2):172-85 [18499469.001]
  • [Cites] Leuk Lymphoma. 2007 Jun;48(6):1228-30 [17577791.001]
  • [Cites] Blood Rev. 2007 Jul;21(4):183-200 [17289231.001]
  • [Cites] Am J Clin Pathol. 2007 Feb;127(2):176-81 [17210522.001]
  • [Cites] Arch Ophthalmol. 2006 Nov;124(11):1601-6 [17102008.001]
  • [Cites] Mayo Clin Proc. 2005 Oct;80(10):1371-82 [16212152.001]
  • [Cites] Am J Clin Pathol. 2002 Apr;117(4):606-14 [11939736.001]
  • [Cites] Blood. 1993 May 15;81(10):2658-63 [8490175.001]
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):291-300 [15101714.001]
  • [Cites] Leuk Lymphoma. 2004 Jan;45(1):61-5 [15061198.001]
  • [Cites] Am J Clin Pathol. 2004 Apr;121(4):482-8 [15080299.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2996-3001 [12351413.001]
  • [Cites] N Engl J Med. 1994 Mar 31;330(13):920-7 [8114865.001]
  • (PMID = 19294010.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2655153
  • [Keywords] NOTNLM ; CD19 / IgM plasma cell myeloma / Waldenstrom's macroglobulinemia / cerebral hemorrhage / cryoglobulinemia / hyperviscosity syndrome / lymphoplasmacytic lymphoma / plasma cell leukemia
  •  go-up   go-down


62. Alvarez-Twose I, Vano-Galvan S, Calvo-Villas JM, Carreter E, Piqué E, Palacios S: Metastatic cutaneous plasmacytoma presenting as a perianal giant mass. Dermatol Online J; 2008;14(9):17
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are 4 types of plasma-cell neoplasia: classic multiple myeloma (MM), extramedullary plasmacytoma without MM, solitary plasmacytoma of bone, and plasma-cell leukemia.
  • Cutaneous involvement may be seen in all 4 types of plasma-cell neoplasia.
  • It usually occurs in late stages of MM as a reflection of increased tumor cell burden.
  • Primary cutaneous plasmacytoma is defined as monoclonal proliferation of plasma-cells that arises primarily in the skin without evidence of systemic disease.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19061599.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; VAD protocol
  •  go-up   go-down


63. Bernal M, Garrido P, Jiménez P, Carretero R, Almagro M, López P, Navarro P, Garrido F, Ruiz-Cabello F: Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells. Hum Immunol; 2009 Oct;70(10):854-7
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells.
  • In this study, we examined immunogenic differences in bone marrow plasma cells among individuals without gammopathy (controls) and patients with MGUS, multiple myeloma (MM), and plasma cell leukemia.
  • We detected differences in major histocompatibility complex (MHC) class I expression, MHC class I chain-related molecule A, and CD95 that were more evident between MGUS and MM samples; there appeared to be a critical imbalance between natural killer (NK)-cell activating and inhibitory signals during the transition from MGUS to MM.
  • Our results indicate that the human leukocyte antigen (HLA) class I(bright), MICA(dim/-), and CD95(dim/-) immunophenotype reported in myeloma cells may result from an extensive interaction of malignant cells with cytotoxic T and NK cells and appears to be immunoedited for the evasion of immunosurveillance.
  • [MeSH-major] Killer Cells, Natural / immunology. Multiple Myeloma / immunology. Receptors, KIR / immunology. Receptors, Natural Cytotoxicity Triggering / immunology. T-Lymphocytes, Cytotoxic / immunology. Tumor Escape

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19580833.001).
  • [ISSN] 1879-1166
  • [Journal-full-title] Human immunology
  • [ISO-abbreviation] Hum. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Histocompatibility Antigens Class I; 0 / Receptors, KIR; 0 / Receptors, Natural Cytotoxicity Triggering
  •  go-up   go-down


64. Martín-Ayuso M, Almeida J, Pérez-Andrés M, Cuello R, Galende J, González-Fraile MI, Martín-Nuñez G, Ortega F, Rodríguez MJ, San Miguel JF, Orfao A: Peripheral blood dendritic cell subsets from patients with monoclonal gammopathies show an abnormal distribution and are functionally impaired. Oncologist; 2008 Jan;13(1):82-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral blood dendritic cell subsets from patients with monoclonal gammopathies show an abnormal distribution and are functionally impaired.
  • Objectives. The information currently available about dendritic cells (DCs) in patients with different types of monoclonal gammopathy (MG) is limited and frequently controversial.
  • Methods. For this purpose, 61 untreated patients in total with MG were analyzed-MG of undetermined significance (MGUS), 29 cases; multiple myeloma (MM), 28 cases; and plasma cell leukemia (PCL), 4 cases-in comparison with a group of 10 healthy controls.
  • [MeSH-minor] Aged. Aged, 80 and over. Case-Control Studies. Dendritic Cells / pathology. Female. Humans. Leukemia, Plasma Cell / blood. Leukemia, Plasma Cell / physiopathology. Male. Middle Aged. Multiple Myeloma / blood. Multiple Myeloma / physiopathology. Phenotype

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18245015.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


65. Nolan KD, Mone MC, Nelson EW: Plasma cell neoplasms. Review of disease progression and report of a new variant. Surg Oncol; 2005 Aug;14(2):85-90
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell neoplasms. Review of disease progression and report of a new variant.
  • Plasma cell neoplasms are generally categorized into four groups; multiple myeloma (MM), solitary plasmacytoma of the bone (SPB), plasma cell leukemias, and extramedullary plasmacytomas (EMP).
  • A plasmacytoma is defined as any discrete, usually solitary mass of neoplastic plasma cells, either in the bone marrow or in various soft tissue sites.
  • Each manifestation of a plasma cell neoplasm differs in terms of tumor recurrence and progression to MM.
  • This pattern of tumor recurrence is unique and the management of gastric plasmacytoma as part of this complex disease is discussed.
  • The continuum of progression between various sites and manifestations of plasma cell manifestations is reviewed including a previously undiscovered sequence of bone disease, gastric disease, and finally multiple myeloma.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Disease Progression. Gastrectomy. Humans. Male. Orthopedic Procedures. Radiotherapy

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15993050.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 24
  •  go-up   go-down


66. Khan KA, Siddiqui NS, Junaid A, Siddiqui S: Non-secretory myeloma: a rare variant of multiple myeloma. J Coll Physicians Surg Pak; 2008 Sep;18(9):576-7
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The spectrum of plasma cell neoplasm represents indolent conditions like Monoclonal Gammopathy of Undetermined Significance (MGUS) to more aggressive multiple myeloma and plasma cell leukemia.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803898.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Glucocorticoids; 0 / Myeloma Proteins; Q41OR9510P / Melphalan; VB0R961HZT / Prednisone
  •  go-up   go-down


67. Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH, Mendy D, Lopez-Girona A, Tran T, Sapinoso L, Fang W, Xu S, Hampton G, Bartlett JB, Schafer P: Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets; 2010 Mar;10(2):155-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.
  • To determine the effect of dexamethasone on the antimyeloma effects of lenalidomide, we tested in vitro proliferation, tumor suppressor gene expression, caspase activity, cell cycling, and apoptosis levels in a series of multiple myeloma (MM) and plasma cell leukemia cell lines treated with lenalidomide and dexamethasone, alone or in combination.
  • The effect of dexamethasone on the immunomodulatory activities of lenalidomide such as T cell and natural killer (NK) cell activation was measured via interleukin [IL]-2 production, and interferon-gamma and granzyme B production respectively.
  • Lenalidomide inhibited proliferation in most cell lines tested, and this effect was enhanced by dexamethasone.
  • This effect was observed in MM cells containing the high-risk cytogenetic abnormalities t(4;14), t(14;16), del17p, del13, and hypodiploidy.
  • Mechanistically, lenalidomide plus dexamethasone synergistically induced expression of the tumor suppressor genes Egr1, Egr2, Egr3, p15, p21, and p27 in MM cell lines and MM patient cells.
  • The combination activated caspases 3, 8, and 9; and induced cell cycle arrest and apoptosis.
  • Lenalidomide alone increased T cell production of IL-2, and NK cell production of interferon-gamma and granzyme B.
  • [MeSH-major] Dexamethasone / therapeutic use. Killer Cells, Natural / immunology. Multiple Myeloma / drug therapy. T-Lymphocytes / immunology. Thalidomide / analogs & derivatives
  • [MeSH-minor] Adenosine Triphosphate / metabolism. Apoptosis / drug effects. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Blotting, Western. Caspase Inhibitors. Caspases / metabolism. Cell Proliferation / drug effects. Drug Synergism. Gene Expression Profiling. Humans. Immunomodulation / drug effects. Interferon-gamma / metabolism. Interleukin-2 / metabolism. Oligonucleotide Array Sequence Analysis. Phosphorylation / drug effects. Retinoblastoma Protein / metabolism. Tumor Cells, Cultured. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20088798.001).
  • [ISSN] 1873-5576
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Caspase Inhibitors; 0 / Interleukin-2; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Proteins; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone; 82115-62-6 / Interferon-gamma; 8L70Q75FXE / Adenosine Triphosphate; EC 3.4.22.- / Caspases; F0P408N6V4 / lenalidomide
  •  go-up   go-down


68. Fernandes MS, Gomes EM, Butcher LD, Hernandez-Alcoceba R, Chang D, Kansopon J, Newman J, Stone MJ, Tong AW: Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene. Clin Cancer Res; 2009 Aug 1;15(15):4847-56
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene.
  • AdEHCD40L inhibited MM cell growth more effectively than AdEHNull.
  • AdEHCD40L induced apoptosis and S-phase cell cycle blockade while uniquely up-regulating the previously described proapoptotic elements tumor necrosis factor-related apoptosis-inducing ligand, Fas, and IL-8.
  • The direct growth-inhibitory activity of AdEHCD40L, together with the well-known immune-potentiating features of CD40L, may be clinically applicable for the experimental treatment of MM or plasma cell leukemia.
  • [MeSH-minor] Adenoviridae Infections / virology. Animals. Apoptosis / physiology. Cell Cycle / physiology. Cell Line, Tumor. Cytokines / metabolism. Humans. Mice. Mice, SCID. Oligonucleotide Array Sequence Analysis. Proteomics. Transduction, Genetic. Transgenes / genetics. Transgenes / physiology. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19622582.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenovirus E1A Proteins; 0 / Cytokines; 147205-72-9 / CD40 Ligand
  •  go-up   go-down


69. Agnelli L, Mosca L, Fabris S, Lionetti M, Andronache A, Kwee I, Todoerti K, Verdelli D, Battaglia C, Bertoni F, Deliliers GL, Neri A: A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer; 2009 Jul;48(7):603-14
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We firstly generated genome-wide profiles of 41 MMs and four plasma cell leukemias, using a self-developed procedure to infer exact local copy numbers (CNs) for each sample.
  • A multiclass analysis of transcriptional profiles characterizing the different clusters showed marked gene-dosage effects, particularly concerning 1q transcripts; this finding was also confirmed by a nonparametric analysis between normalized gene expression levels and local CN variations (1027 highly-significant correlated genes).

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19396863.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Proteins; EC 1.- / Oxidoreductases; EC 1.1.1.- / WWOX protein, human
  •  go-up   go-down


70. Gustafsson K, Wang X, Severa D, Eriksson M, Kimby E, Merup M, Christensson B, Flygare J, Sander B: Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation. Int J Cancer; 2008 Sep 1;123(5):1025-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endogenous and synthetic cannabinoids exert antiproliferative and proapoptotic effects in various types of cancer and in mantle cell lymphoma (MCL).
  • In this study, we evaluated the expression of cannabinoid receptors type 1 and type 2 (CB1 and CB2) in non-Hodgkin lymphomas of B cell type (n = 62).
  • In functional studies using MCL, Burkitt lymphoma (BL), chronic lymphatic leukemia (CLL) and plasma cell leukemia cell lines, the stable anandamide analog R(+)-methanandamide (R(+)-MA) induced cell death only in MCL and CLL cells, which overexpressed both cannabinoid receptors, but not in BL.
  • [MeSH-major] Antimitotic Agents / pharmacology. Arachidonic Acids / pharmacology. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Mantle-Cell / drug therapy. Receptor, Cannabinoid, CB1 / metabolism. Receptor, Cannabinoid, CB2 / metabolism
  • [MeSH-minor] Animals. Apoptosis / drug effects. Blotting, Western. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / metabolism. Cell Proliferation / drug effects. DNA, Complementary / analysis. DNA, Neoplasm / analysis. Enzyme-Linked Immunosorbent Assay. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Leukemia, Plasma Cell / drug therapy. Leukemia, Plasma Cell / metabolism. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / metabolism. Mice. Mice, Inbred NOD. Mice, SCID. Mitosis / drug effects. Mitotic Index. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transplantation, Heterologous. Up-Regulation

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18546271.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimitotic Agents; 0 / Arachidonic Acids; 0 / DNA, Complementary; 0 / DNA, Neoplasm; 0 / RNA, Messenger; 0 / Receptor, Cannabinoid, CB1; 0 / Receptor, Cannabinoid, CB2; 150314-39-9 / methanandamide
  •  go-up   go-down


71. Kumar S, Kimlinger T, Morice W: Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol; 2010 Sep;23(3):433-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotyping in multiple myeloma and related plasma cell disorders.
  • Plasma cell disorders form a spectrum ranging from the asymptomatic presence of small monoclonal populations of plasma cells to conditions like plasma cell leukemia and multiple myeloma, in which the bone marrow can be replaced by the accumulation of neoplastic plasma cells.
  • Immunophenotyping has become an invaluable tool in the management of hematological malignancies and is increasingly finding a role in the diagnosis and monitoring of plasma cell disorders.
  • This, along with a better understanding of the phenotypic heterogeneity of the clonal plasma cells in different disorders, has made immunophenotyping an indispensible tool in the diagnosis, prognostic classification and management of plasma cell disorders.
  • This book chapter addresses the approaches taken to evaluate monoclonal plasma cell disorders, and the different markers and techniques that are important for the study of these diseases.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Blood. 2006 Dec 15;108(13):4194-7 [16946299.001]
  • [Cites] Blood. 2007 Jun 1;109(11):5002-10 [17311991.001]
  • [Cites] Arch Pathol Lab Med. 2007 Jun;131(6):951-5 [17550325.001]
  • [Cites] Leukemia. 2007 Sep;21(9):2043-6 [17460704.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2586-92 [17576818.001]
  • [Cites] Bone Marrow Transplant. 2007 Dec;40(11):1033-7 [17891186.001]
  • [Cites] Leuk Lymphoma. 2008 Feb;49(2):298-305 [18231917.001]
  • [Cites] Semin Immunol. 2008 Feb;20(1):49-58 [18222702.001]
  • [Cites] Haematologica. 2008 Mar;93(3):431-8 [18268286.001]
  • [Cites] Leuk Res. 2008 Mar;32(3):379-82 [17767956.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3403-6 [18216299.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2737-44 [18443352.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4017-23 [18669875.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):882-5 [12060125.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3095-100 [12384404.001]
  • [Cites] Blood. 2003 Feb 1;101(3):827-30 [12393530.001]
  • [Cites] Br J Haematol. 2003 Apr;121(1):36-43 [12670329.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3136-41 [12480692.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):749-57 [12780789.001]
  • [Cites] Immunol Rev. 2003 Aug;194:105-11 [12846811.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1070-1 [12702507.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1075-7 [12714489.001]
  • [Cites] Amyloid. 2003 Jun;10(2):110-6 [12964418.001]
  • [Cites] Blood Cells Mol Dis. 2004 Mar-Apr;32(2):293-301 [15003821.001]
  • [Cites] Am J Clin Pathol. 2004 Apr;121(4):482-8 [15080299.001]
  • [Cites] Haematologica. 2004 May;89(5):547-51 [15136217.001]
  • [Cites] Br J Haematol. 2004 Sep;126(5):665-74 [15327517.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2281-9 [15512818.001]
  • [Cites] Br J Haematol. 1968 Oct;15(4):417-20 [4176071.001]
  • [Cites] Blood. 1980 Mar;55(3):364-72 [7357075.001]
  • [Cites] J Clin Pathol. 1982 Jan;35(1):63-8 [6801095.001]
  • [Cites] Blood. 1983 Jul;62(1):166-71 [6407546.001]
  • [Cites] Mod Pathol. 2009 Jun;22(6):807-16 [19287458.001]
  • [Cites] J Clin Pathol. 2009 Aug;62(8):724-30 [19638544.001]
  • [Cites] Am J Clin Pathol. 2009 Jul;132(1):60-6 [19864234.001]
  • [Cites] Haematologica. 2009 Nov;94(11):1599-602 [19880781.001]
  • [Cites] Blood. 2009 Nov 12;114(20):4369-72 [19755674.001]
  • [Cites] Br J Haematol. 2010 Jan;148(1):110-4 [19821821.001]
  • [Cites] Br J Haematol. 2010 May;149(3):334-51 [20201947.001]
  • [Cites] Haematologica. 2010 Jun;95(6):1016-20 [20081059.001]
  • [Cites] Cytometry B Clin Cytom. 2010 Jul;78(4):239-52 [20155853.001]
  • [Cites] Cytometry. 1999 Dec 15;38(6):286-92 [10589044.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):3096-104 [10850462.001]
  • [Cites] Blood. 2001 Jul 1;98(1):187-93 [11418479.001]
  • [Cites] Bone Marrow Transplant. 2001 Nov;28(10):957-62 [11753551.001]
  • [Cites] J Immunol Methods. 1991 Nov 22;144(2):253-6 [1683667.001]
  • [Cites] Ann Hematol. 1992 Mar;64(3):132-9 [1373957.001]
  • [Cites] Aust N Z J Med. 1992 Jun;22(3):291-302 [1497556.001]
  • [Cites] Blood. 1993 May 15;81(10):2658-63 [8490175.001]
  • [Cites] Blood. 1993 Jun 15;81(12):3382-7 [8507875.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):108-13 [8508395.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2597-603 [7522634.001]
  • [Cites] Br J Haematol. 1994 Jun;87(2):266-72 [7947266.001]
  • [Cites] Blood. 1995 Jan 15;85(2):436-47 [7529064.001]
  • [Cites] Cancer Res. 1995 Aug 15;55(16):3647-53 [7543019.001]
  • [Cites] Blood. 1996 Sep 1;88(5):1780-7 [8781435.001]
  • [Cites] Cytometry. 1996 Jun 15;26(2):113-20 [8817086.001]
  • [Cites] Br J Haematol. 1996 Dec;95(3):489-93 [8943889.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1655-65 [9626070.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1521-6 [9626472.001]
  • [Cites] Leukemia. 2002 Jan;16(1):135-43 [11840273.001]
  • [Cites] Br J Haematol. 2002 Feb;116(2):273-7 [11841427.001]
  • [Cites] N Engl J Med. 2002 Feb 21;346(8):564-9 [11856795.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2172-8 [11877294.001]
  • [Cites] Am J Hematol. 1985 Nov;20(3):289-92 [3904417.001]
  • [Cites] Mayo Clin Proc. 1987 Nov;62(11):969-77 [3118117.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):1041-6 [3286829.001]
  • [Cites] Blood. 1988 Jul;72(1):219-23 [3291982.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):859-62 [2914294.001]
  • [Cites] Blood. 1990 Jul 15;76(2):377-82 [1695113.001]
  • [Cites] Blood. 1990 Nov 1;76(9):1739-47 [2224123.001]
  • [Cites] Br J Haematol. 1991 Feb;77(2):185-90 [1706197.001]
  • [Cites] Clin Exp Immunol. 1991 Mar;83(3):418-22 [1706237.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3887-97 [9808582.001]
  • [Cites] Leukemia. 1998 Nov;12(11):1821-8 [9823960.001]
  • [Cites] Leukemia. 1998 Dec;12(12):1977-82 [9844928.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1032-7 [9920853.001]
  • [Cites] Br J Haematol. 1999 Jan;104(1):131-7 [10027725.001]
  • [Cites] Br J Haematol. 1999 Jan;104(1):138-43 [10027726.001]
  • [Cites] Br J Haematol. 1999 Oct;107(1):121-31 [10520032.001]
  • [Cites] Nat Rev Immunol. 2005 Mar;5(3):230-42 [15738953.001]
  • [Cites] Annu Rev Immunol. 2005;23:487-513 [15771579.001]
  • [Cites] Haematologica. 2005 Apr;90(4):489-93 [15820944.001]
  • [Cites] Leuk Res. 2005 Aug;29(8):961-6 [15978948.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5668-74 [16110026.001]
  • [Cites] Haematologica. 2005 Oct;90(10):1300B [16219557.001]
  • [Cites] Haematologica. 2005 Oct;90(10):1365-72 [16219573.001]
  • [Cites] Leukemia. 2005 Nov;19(11):2021-2 [16167057.001]
  • [Cites] Br J Haematol. 2006 Jan;132(2):168-70 [16398651.001]
  • [Cites] N Engl J Med. 2006 Mar 30;354(13):1362-9 [16571879.001]
  • [Cites] Br J Haematol. 2006 Jun;133(5):530-2 [16681641.001]
  • [Cites] Mayo Clin Proc. 2006 May;81(5):693-703 [16706268.001]
  • [Cites] Eur J Haematol. 2006 Jul;77(1):14-8 [16827882.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):545-51 [16938662.001]
  • [Cites] Nat Rev Immunol. 2006 Oct;6(10):741-50 [16977339.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1577-8 [17043027.001]
  • (PMID = 21112041.001).
  • [ISSN] 1532-1924
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090628-10; United States / NCI NIH HHS / CA / K12 CA090628; United States / NCI NIH HHS / CA / K12 CA090628-10
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS246587; NLM/ PMC3005703
  •  go-up   go-down


72. Han X, Kilfoy B, Zheng T, Holford TR, Zhu C, Zhu Y, Zhang Y: Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. Cancer Causes Control; 2008 Oct;19(8):841-58
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With the incidence and prevalence of lymphoid neoplasms increasing, a comparison of survival patterns by subtype may provide critical clues for improving the disease burden.
  • The best survival was observed for Hodgkin lymphoma among young patients, and the worst survival was observed among cases with plasma cell neoplasms, particularly plasma cell leukemia, in all racial groups.
  • Males typically had lower survival rates than females, but the opposite was observed for Burkitt lymphoma/leukemia among non-whites and multiple myeloma among non-Hispanic whites.
  • Survival rates decline with age at diagnosis among elders, while the patterns were diverse by subtype among younger cases.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365759.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / FIC NIH HHS / TW / D43 TW007864; United States / FIC NIH HHS / TW / 1D43TW007864-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  •  go-up   go-down


73. Chang H, Qi XY, Claudio J, Zhuang L, Patterson B, Stewart AK: Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res; 2006 Mar;30(3):262-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clonal plasma cells from patients with multiple myeloma (MM), plasma cell leukemia (PCL) and human myeloma cell lines (HMCLs) were analyzed for deletions/mutations of the tumor suppressor gene PTEN.
  • PTEN deletions were detected in 4 MM patients at diagnosis with stage III disease (Durie-Salmon).
  • Our results indicate that alterations of PTEN are uncommon in MM patients, and PTEN deletions tend to occur in advanced disease suggesting that they are secondary, rather than primary, events in the pathogenesis of MM.
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Line, Tumor. DNA Mutational Analysis / methods. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112193.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


74. van Stralen E, van de Wetering M, Agnelli L, Neri A, Clevers HC, Bast BJ: Identification of primary MAFB target genes in multiple myeloma. Exp Hematol; 2009 Jan;37(1):78-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: We used an inducible system to upregulate MAFB in MM cell lines not carrying the t(14;20).
  • These genes were further evaluated comparatively with gene expression profiles obtained from MM or plasma cell leukemia tumors carrying an activated MAFB gene.
  • RESULTS: The inducible cell lines identified a total of 284 modulated transcripts.
  • These direct target genes may be responsible for the oncogenic transformation of MAF expressing myeloma cells.
  • [MeSH-minor] Cell Line. Chromosomes, Human, Pair 21 / genetics. Chromosomes, Human, Pair 21 / metabolism. Gene Expression Profiling. Humans. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Heavy Chains / metabolism. Oligonucleotide Array Sequence Analysis. Proto-Oncogene Proteins c-maf / genetics. Proto-Oncogene Proteins c-maf / metabolism. Quantitative Trait Loci / genetics. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19013005.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / MAF protein, human; 0 / MAFB protein, human; 0 / MafB Transcription Factor; 0 / Proto-Oncogene Proteins c-maf
  •  go-up   go-down


75. Parker H, Cheung KL, Robinson HM, Harrison CJ, Strefford JC: Cytogenetic and genomic characterization of cell line ARH77. Cancer Genet Cytogenet; 2008 Feb;181(1):40-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic and genomic characterization of cell line ARH77.
  • The cell line ARH77 is derived from a patient with plasma cell leukemia and has a complex and continually evolving karyotype.
  • It is frequently used in biological studies of myeloma and plasma cell leukemia, so accurate characterization of the genome is valuable.
  • Conventional cytogenetics and M-FISH indicated the location and types of the major chromosomal changes, whether balanced or unbalanced, and at the same time demonstrated the level of karyotypic evolution between cells.
  • [MeSH-major] Leukemia, Plasma Cell / genetics
  • [MeSH-minor] Cell Line, Tumor. Chromosome Banding. Chromosome Mapping. Gene Expression Profiling. Genome, Human. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Nucleic Acid Hybridization. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18262052.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


76. Sharma A, Kaushal M, Chaturvedi NK, Yadav R: Cytodiagnosis of multiple myeloma presenting as orbital involvement: a case report. Cytojournal; 2006;3:19

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Plasma cell neoplasms represent autonomous proliferations of plasma cells and can manifest as diffuse myeloma with systemic involvement (plasma cell myeloma or multiple myeloma), monoclonal gammopathy of undetermined significance (MGUS), or as variants of plasma cell myeloma such as indolent myeloma, smoldering myeloma, osteosclerotic myeloma, plasma cell leukaemia and non-secretory myeloma.
  • Localized neoplastic proliferation of plasma cells presents as solitary plasmacytoma of bone or extramedullary plasmacytoma.
  • Early cytological diagnosis of such lesions is vital for timely institution of appropriate therapy.
  • As far as we are aware only six previous cases of cytological diagnosis of multiple myeloma involving the orbit are on record.
  • A fine needle aspirate from the temporal region swelling showed features of a plasmacytoma, and subsequent workup confirmed the presence of systemic disease.
  • A final diagnosis of multiple myeloma with orbital involvement at presentation was made.
  • Fine needle aspiration diagnosis of plasmacytoma at extramedullary sites offers an opportunity for non-invasive verification of systemic involvement, and thus plays a major role in early diagnosis and management of these patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Cytol. 1995 Jan-Feb;39(1):104-10 [7846996.001]
  • [Cites] Arch Ophthalmol. 1972 Jan;87(1):30-5 [4550269.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1):111-6 [9894461.001]
  • [Cites] Arch Ophthalmol. 1977 Apr;95(4):642-4 [849187.001]
  • [Cites] Cytometry. 2001 Feb 15;46(1):23-7 [11241503.001]
  • [Cites] Tumori. 2005 May-Jun;91(3):270-2 [16206655.001]
  • [Cites] Am J Clin Pathol. 2004 Apr;121(4):482-8 [15080299.001]
  • [Cites] Br J Ophthalmol. 1953 Sep;37(9):543-54 [13081952.001]
  • [Cites] Cancer. 2001 Aug 25;93(4):257-62 [11507699.001]
  • [Cites] Surv Ophthalmol. 1987 Mar-Apr;31(5):343-51 [3603371.001]
  • (PMID = 16901345.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1564147
  •  go-up   go-down


77. Cheema PK, Zadeh S, Kukreti V, Reece D, Chen C, Trudel S, Mikhael J: Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant. Biol Blood Marrow Transplant; 2009 Jun;15(6):686-93
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
  • The objective of this study is to describe presenting features and outcomes of patients < or =40 years of age with MM who undergo autologous stem cell transplantation (ASCT) as first-line treatment, and compare overall survival (OS) and progression free survival (PFS) to patients aged 41-65 years.
  • We performed a retrospective institutional review of all patients < or =40 years of age and 41-65 years of age at the time of diagnosis of MM who had undergone upfront ASCT from January 1, 1990, to July 31, 2007.
  • There was a high rate of plasma cell leukemia (PCL) in young patients at 11% compared to the reported rate of 2%-4%.
  • At diagnosis, there was an increased rate of renal failure in the young cohort compared to patients aged 41-65 years at 25% versus 16% and Bence Jones proteinuria at 81% versus 51%.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Incidence. Kaplan-Meier Estimate. Leukemia, Plasma Cell / epidemiology. Male. Middle Aged. Neoplasms, Second Primary / epidemiology. Postoperative Complications / epidemiology. Prognosis. Renal Insufficiency / epidemiology. Renal Insufficiency / etiology. Retrospective Studies. Survival Rate. Transplantation Conditioning / methods. Transplantation Conditioning / statistics & numerical data. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19450753.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Longo MS, Carone DM, NISC Comparative Sequencing Program, Green ED, O'Neill MJ, O'Neill RJ: Distinct retroelement classes define evolutionary breakpoints demarcating sites of evolutionary novelty. BMC Genomics; 2009;10:334
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed the orthologous human EB (14q32.33), known to be associated with translocations in many cancers including multiple myelomas and plasma cell leukemias, and found a conserved distribution of similar repetitive elements.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytogenet Genome Res. 2004;107(1-2):115-8 [15305065.001]
  • [Cites] J Virol. 2004 Aug;78(16):8788-98 [15280487.001]
  • [Cites] Genome Res. 2004 Oct;14(10A):1851-60 [15364903.001]
  • [Cites] Nucleic Acids Res. 1982 Dec 20;10(24):8155-70 [6819544.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Feb;81(3):814-8 [6583681.001]
  • [Cites] Cytogenet Cell Genet. 1996;73(1-2):123-9 [8646879.001]
  • [Cites] Blood. 1997 Jul 15;90(2):526-34 [9226151.001]
  • [Cites] J Virol. 1998 Mar;72(3):1870-5 [9499038.001]
  • [Cites] Mol Biol Evol. 1998 May;15(5):611-2 [9580992.001]
  • [Cites] Nature. 1998 May 7;393(6680):68-72 [9590690.001]
  • [Cites] Leuk Lymphoma. 1998 May;29(5-6):563-75 [9643570.001]
  • [Cites] Genome Res. 2004 Nov;14(11):2235-44 [15479945.001]
  • [Cites] J Virol. 2005 Jan;79(1):341-52 [15596828.001]
  • [Cites] Hum Mutat. 2005 Jan;25(1):45-55 [15580561.001]
  • [Cites] Genome Res. 2005 Jan;15(1):98-110 [15590940.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3354-9 [15718282.001]
  • [Cites] J Hered. 2005 May-Jun;96(3):217-24 [15653556.001]
  • [Cites] Science. 2005 Jul 22;309(5734):613-7 [16040707.001]
  • [Cites] Trends Genet. 2006 Jun;22(6):297-301 [16678302.001]
  • [Cites] BMC Bioinformatics. 2006;7:474 [17064419.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2006;7:407-42 [16780417.001]
  • [Cites] Genome Biol. 2006;7(12):R115 [17156441.001]
  • [Cites] Mutat Res. 2007 Mar 1;616(1-2):46-59 [17157332.001]
  • [Cites] Nature. 2007 Mar 29;446(7135):507-12 [17392779.001]
  • [Cites] Genetics. 2007 Dec;177(4):2507-17 [18073443.001]
  • [Cites] Genome Biol. 2007;8(8):R170 [17708770.001]
  • [Cites] Genome Res. 2008 Mar;18(3):370-9 [18230801.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11845-50 [18701715.001]
  • [Cites] Chromosoma. 2009 Feb;118(1):113-25 [18839199.001]
  • [Cites] Genome Res. 2009 Feb;19(2):178-90 [19029537.001]
  • [Cites] Chromosome Res. 1999;7(6):461-74 [10560969.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Apr;30(4):349-63 [11241788.001]
  • [Cites] Mamm Genome. 2001 Mar;12(3):256-9 [11252178.001]
  • [Cites] Chromosome Res. 2001;9(4):301-8 [11419794.001]
  • [Cites] J Mol Evol. 2001 Sep;53(3):237-43 [11523010.001]
  • [Cites] Genomics. 2002 Sep;80(3):331-43 [12213204.001]
  • [Cites] Genome Res. 2003 Jan;13(1):37-45 [12529304.001]
  • [Cites] Nature. 2003 Feb 6;421(6923):601-7 [12508121.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7672-7 [12810957.001]
  • [Cites] Cytogenet Genome Res. 2003;102(1-4):282-90 [14970718.001]
  • [Cites] Genome Res. 2004 Apr;14(4):507-16 [15059991.001]
  • [Cites] J Hered. 2004 Sep-Oct;95(5):375-81 [15388765.001]
  • (PMID = 19630942.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Euchromatin
  • [Other-IDs] NLM/ PMC2736999
  •  go-up   go-down


79. Takemura Y, Ikeda M, Kobayashi K, Nakazawa Y, Mori Y, Mitsuishi T, Ishigame H, Kameko F, Fujita K, Ichinohasama R: Plasma cell leukemia producing monoclonal immunoglobulin E. Int J Hematol; 2009 Oct;90(3):402-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukemia producing monoclonal immunoglobulin E.
  • A 78-year-old male with lumbar pain and dim consciousness presented the clinical pictures of plasma cell leukemia (PCL) producing a large amount of monoclonal immunoglobulin E (IgE)/kappa protein.
  • Circulating plasma cells demonstrated CD19(-)/CD56(-) and MPC-1(-)/CD49e(-)/CD45(+/-), the latter indicating the immature phenotype of the tumor cells.
  • Bone marrow was occupied with immature, atypical plasma cells, of which cytoplasms were positive for IgE by direct immunofluorescence analysis.
  • The clinical and biological characteristics of IgE-producing PCL, a very rare type of plasma cell dyscrasia, are discussed, reviewing the past literature.
  • [MeSH-major] Antibodies, Monoclonal / blood. Bone Neoplasms / immunology. Immunoglobulin E / blood. Immunoglobulin kappa-Chains / blood. Leukemia, Plasma Cell / immunology

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19728026.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulin kappa-Chains; 37341-29-0 / Immunoglobulin E
  • [Number-of-references] 28
  •  go-up   go-down


80. Turken O, Basekim C, Haholu A, Karagoz B, Bilgi O, Ozgun A, Kucukardali Y, Narin Y, Yazgan Y, Kandemir EG: Hyperammonemic encephalopathy in a patient with primary hepatic neuroendocrine carcinoma. Med Oncol; 2009;26(3):309-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are case reports of hyperammonemia with some malignancies such as multiple myeloma, plasma cell leukemia, and leiomyosarcoma, or in some patients who have received chemotherapy.

  • Genetic Alliance. consumer health - Hepatic encephalopathy.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19031017.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Nau KC, Lewis WD: Multiple myeloma: diagnosis and treatment. Am Fam Physician; 2008 Oct 1;78(7):853-9
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple myeloma: diagnosis and treatment.
  • The disease is diagnosed with serum or urine protein electrophoresis or immunofixation and bone marrow aspirate analysis.
  • Nuclear bone scans and dual energy x-ray absorptiometry have no role in the diagnosis and staging of myeloma.
  • The differential diagnosis of monoclonal gammopathies includes monoclonal gammopathy of uncertain significance, smoldering (asymptomatic) and symptomatic multiple myeloma, amyloidosis, B-cell non-Hodgkin lymphoma, Waldenström macroglobulinemia, and rare plasma cell leukemia and heavy chain diseases.
  • Symptomatic multiple myeloma is treated with chemotherapy followed by autologous stem cell transplantation, if possible.
  • [MeSH-major] Multiple Myeloma / diagnosis. Multiple Myeloma / therapy
  • [MeSH-minor] Age Factors. Humans. Myeloma Proteins / physiology. Pain / etiology. Plasma Cells / physiology. Risk Factors

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18841734.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloma Proteins; 0 / multiple myeloma M-proteins
  • [Number-of-references] 29
  •  go-up   go-down


82. Martín P, Santón A, García-Cosío M, Bellas C: RAS mutations are uncommon in multiple myeloma and other monoclonal gammopathies. Int J Oncol; 2005 Oct;27(4):1023-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Monoclonal gammopathies are a group of diseases characterised by the proliferation of a single clone of plasma cells that produce a homogeneous monoclonal protein (M protein or myeloma protein) that consist of two heavy polypeptide chains of the same class and subclass and two light polypeptide chains of the same type.
  • In this study, we have analysed K-ras codon 12 and N-ras codon 61 mutations on anti-CD138 sorted bone marrow plasma cell samples of 44 cases of monoclonal gammopathies: 30 MM, 13 MGUS and 1 plasma cell leukaemia, using polymerase chain reaction.
  • [MeSH-minor] Alleles. Bone Marrow / metabolism. Bone Marrow Cells / cytology. Codon. DNA Primers / chemistry. Female. Humans. Membrane Glycoproteins / biosynthesis. Myeloma Proteins / metabolism. Peptides / chemistry. Point Mutation. Polymerase Chain Reaction. Proteoglycans / biosynthesis. Sensitivity and Specificity. Sequence Analysis, DNA. Spain. Syndecan-1. Syndecans

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142319.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Codon; 0 / DNA Primers; 0 / Membrane Glycoproteins; 0 / Myeloma Proteins; 0 / Peptides; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans; 0 / multiple myeloma M-proteins
  •  go-up   go-down


83. Liebisch P, Eppinger S, Schöpflin C, Stehle G, Munzert G, Döhner H, Schmid M: CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. Haematologica; 2005 Apr;90(4):489-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVES: Despite recent advances in the treatment of multiple myeloma (MM), this disease remains incurable in the majority of patients.
  • To investigate the applicability of this compound to clonal plasma cell disorders, we analyzed CD44v6 expression on malignant plasma cells from patients with multiple myeloma.
  • DESIGN AND METHODS: Bone marrow samples from 57 patients with monoclonal gammopathy of undetermined significance (MGUS), MM, and plasma cell leukemia (PCL) were examined for CD44v6 expression by using flow cytometry (FACS) analysis.
  • RESULTS: In only 1 of 16 cases (6%) with MGUS and 1 out of 6 cases (17%) with stage I MM were plasma cells CD44v6 positive.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Female. Humans. Leukemia, Plasma Cell / drug therapy. Leukemia, Plasma Cell / genetics. Leukemia, Plasma Cell / immunology. Male. Middle Aged. Paraproteinemias / drug therapy. Paraproteinemias / genetics. Paraproteinemias / immunology. Tumor Burden / immunology

  • Genetic Alliance. consumer health - Chromosome 13q Deletion.
  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2005 Apr;90(4):436-7 [15820931.001]
  • (PMID = 15820944.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD44; 0 / Antineoplastic Agents; 0 / CD44v6 antigen; 0 / Glycoproteins
  •  go-up   go-down


84. Kouno T, Watanabe T, Umeda T, Beppu Y, Kojima R, Sungwon K, Kobayashi Y, Tobinai K, Hasegawa T, Matsuno Y: CD56-positive small round cell tumor: osseous plasmacytoma manifested in osteolytic tumors of the iliac bone and femora. Jpn J Clin Oncol; 2005 Feb;35(2):90-3
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD56-positive small round cell tumor: osseous plasmacytoma manifested in osteolytic tumors of the iliac bone and femora.
  • Monoclonal gammopathy of undetermined significance does not overexpress cluster of differentiation (CD) 56, but plasma cell myeloma frequently overexpressed it.
  • However, plasma cell leukemia and extramedullary plasmacytoma usually down-regulate CD56 expression.
  • Plasmacytoma, especially 'solitary plasmacytoma of bone', is difficult to diagnose as plasma cell neoplasm, because it occasionally appears similar to other bone tumors, both clinically and pathologically, and is rarely accompanied by monoclonal protein in the serum or urine.
  • The present case was a patient with an osteolytic 'small round cell tumor' of the iliac bone, which also invaded the femora.
  • An immunohistopathological finding of CD56 expression played a key role in making a diagnosis.
  • The definitive diagnosis of plasmacytoma was made based on the electron microscopic findings.
  • The plasma cells which infiltrated her sternum showed the same restriction to kappa light chain expression in their cytoplasms as that of the iliac bone tumor cells, but did not express CD56.
  • [MeSH-major] Antigens, CD56 / biosynthesis. Bone Neoplasms / diagnosis. Plasmacytoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709094.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD56
  •  go-up   go-down


85. Thuillier D, Lenglet A, Chaby G, Royer R, Vaida I, Viseux V, Dadban A, Billet A, Christophe O, Chatelain D, Marolleau JP, Lok C, Damaj G: [Bortezomib-induced eruption: Sweet syndrome? Two case reports]. Ann Dermatol Venereol; 2009 May;136(5):427-30
Hazardous Substances Data Bank. COLCHICINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Toxidermie au bortézomib : syndrome de Sweet? Deux cas.
  • PATIENTS AND METHODS: Case 1: bortezomib treatment was started in a 62-year-old man for mantle cell lymphoma.
  • Case 2: a 46-year-old woman was receiving bortezomib treatment for plasma cell leukemia.
  • [MeSH-minor] Biopsy. Bortezomib. Colchicine / therapeutic use. Dexamethasone / therapeutic use. Female. Humans. Leukemia, Plasma Cell / etiology. Lymphoma, Mantle-Cell / drug therapy. Male. Middle Aged. Skin Ulcer / chemically induced. Skin Ulcer / pathology. Treatment Outcome

  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19442799.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone; SML2Y3J35T / Colchicine
  •  go-up   go-down


86. Morgan TK, Zhao S, Chang KL, Haddix TL, Domanay E, Cornbleet PJ, Arber DA, Natkunam Y: Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease: an immunohistochemical analysis. Am J Clin Pathol; 2006 Oct;126(4):545-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease: an immunohistochemical analysis.
  • Genome-wide expression studies using complementary DNA microarrays recently suggested a number of intriguing candidate genes for distinguishing plasma cell dyscrasias.
  • Our objective was to test select markers using immunohistochemical analysis and a tissue microarray from paraffin-embedded bone marrow core biopsy specimens obtained from 8 patients with monoclonal gammopathy of undetermined significance, 17 with plasmacytoma, 160 with multiple myeloma, and 15 with plasma cell leukemia (PCL).
  • Each core was scored in duplicate by observers blinded to phenotype and reported as the average percentage of CD138+ cells.
  • Our results support the hypothesis that low CD27 expression correlates with high-risk disease, including primary PCL and decreased progression-free survival in solitary plasmacytoma.
  • [MeSH-major] Antigens, CD27 / metabolism. Leukemia, Plasma Cell / metabolism. Monoclonal Gammopathy of Undetermined Significance / metabolism. Multiple Myeloma / metabolism. Plasma Cells / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Biopsy. Bone Marrow / metabolism. Bone Marrow / pathology. Disease Progression. Humans. Immunohistochemistry. Immunophenotyping. Single-Blind Method. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16938662.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD27; 0 / Biomarkers, Tumor
  •  go-up   go-down


87. Pratz K, Levis M: Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. Leuk Lymphoma; 2008 May;49(5):852-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.
  • FMS-Like-Tyrosine kinase-3 (FLT3) mutations are found in about 30% of cases of acute myeloid leukemia and confer an increased relapse rate and reduced overall survival.
  • Preclinical models suggest that these compounds enhance the cytotoxicity of conventional chemotherapeutics against FLT3 mutant leukemia cells.
  • The combination of FLT3 inhibitors with chemotherapy is also complicated by potential pharmacokinetic obstacles, such as plasma protein binding and p-glycoprotein interactions.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):32892-8 [12815052.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1738-52 [12970773.001]
  • [Cites] Leukemia. 2007 May;21(5):1005-14 [17330105.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4280-90 [17634558.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4575-82 [17671144.001]
  • [Cites] Exp Hematol. 1995 Sep;23(10):1121-9 [7544740.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1089-96 [8562934.001]
  • [Cites] Leukemia. 1996 Feb;10(2):238-48 [8637232.001]
  • [Cites] Leukemia. 1996 Apr;10(4):588-99 [8618433.001]
  • [Cites] Acta Haematol. 1996;95(3-4):218-23 [8677746.001]
  • [Cites] Eur J Immunol. 1996 Jul;26(7):1504-10 [8766553.001]
  • [Cites] J Immunol. 1996 Oct 1;157(7):2953-60 [8816402.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;38(6):571-3 [8823501.001]
  • [Cites] Leukemia. 1996 Dec;10(12):1911-8 [8946930.001]
  • [Cites] Blood. 1998 Mar 15;91(6):1947-58 [9490677.001]
  • [Cites] Leukemia. 1998 Mar;12(3):301-10 [9529123.001]
  • [Cites] J Biol Chem. 1998 Jun 12;273(24):14962-7 [9614102.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1333-7 [9737679.001]
  • [Cites] J Mol Biol. 1999 Jan 15;285(2):713-25 [9878439.001]
  • [Cites] Leukemia. 1999 Jan;13(1):38-43 [10049058.001]
  • [Cites] J Leukoc Biol. 1999 Mar;65(3):372-80 [10080542.001]
  • [Cites] Exp Hematol. 1999 Apr;27(4):663-72 [10210324.001]
  • [Cites] Blood. 1999 May 1;93(9):3074-80 [10216104.001]
  • [Cites] Br J Haematol. 1999 Apr;105(1):155-62 [10233379.001]
  • [Cites] Leukemia. 1999 Sep;13(9):1374-82 [10482988.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4202-9 [15304385.001]
  • [Cites] Blood. 2005 Jan 1;105(1):54-60 [15345597.001]
  • [Cites] Blood. 2005 Feb 1;105(3):986-93 [15459012.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1759-67 [15498859.001]
  • [Cites] Xenobiotica. 2004 Oct;34(10):917-34 [15764411.001]
  • [Cites] Leukemia. 2005 Jun;19(6):930-5 [15815726.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5281-91 [16033847.001]
  • [Cites] Int J Hematol. 2005 Aug;82(2):100-7 [16146839.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35217-27 [16109713.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3737-46 [16585200.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Oct;52(4):307-18 [12827297.001]
  • [Cites] Gene. 2003 Oct 23;317(1-2):49-57 [14604791.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5465-76 [14654525.001]
  • [Cites] Mol Cell. 2004 Jan 30;13(2):169-78 [14759363.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3338-49 [14981546.001]
  • [Cites] Blood. 2004 May 15;103(10):3669-76 [14726387.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] Br J Clin Pharmacol. 2004 Aug;58(2):212-6 [15255805.001]
  • [Cites] Blood. 2004 Aug 15;104(4):1145-50 [15126317.001]
  • [Cites] Br J Haematol. 2004 Oct;127(1):26-33 [15384974.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2912-8 [15242881.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Nov;76(11):5736-40 [42904.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1210-4 [2045861.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2395-401 [10344749.001]
  • [Cites] Br J Haematol. 2001 Jun;113(4):983-8 [11442493.001]
  • [Cites] Curr Med Chem. 2007;14(5):519-30 [17346144.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3400-8 [17209055.001]
  • [Cites] Leukemia. 2007 May;21(5):877-85 [17330097.001]
  • [Cites] Exp Hematol. 2007 Oct;35(10):1522-6 [17889720.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9490-500 [17909059.001]
  • [Cites] J Biol Chem. 2007 Oct 26;282(43):31542-8 [17646169.001]
  • [Cites] Leukemia. 2008 Jan;22(1):138-46 [17943175.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Aug;62(3):439-48 [17960382.001]
  • [Cites] Med Pediatr Oncol. 1999 Dec;33(6):525-9 [10573574.001]
  • [Cites] Leukemia. 2000 Apr;14(4):675-83 [10764154.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3489-97 [10828034.001]
  • [Cites] J Exp Med. 2000 Sep 4;192(5):719-28 [10974037.001]
  • [Cites] Biochim Biophys Acta. 2000 Oct 18;1482(1-2):157-71 [11058758.001]
  • [Cites] Br J Haematol. 2000 Oct;111(1):190-5 [11091200.001]
  • [Cites] Blood. 2001 Jan 1;97(1):89-94 [11133746.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1485-92 [11230495.001]
  • [Cites] Blood. 2001 Apr 1;97(7):1999-2007 [11264164.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2434-9 [11290608.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3589-95 [11369655.001]
  • [Cites] Leukemia. 2001 Jul;15(7):1001-10 [11455967.001]
  • [Cites] Blood. 2001 Aug 1;98(3):885-7 [11468194.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1752-9 [11535508.001]
  • [Cites] Mol Cell. 2001 Sep;8(3):481-2 [11583608.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7233-9 [11585760.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3212-20 [11719356.001]
  • [Cites] J Med Chem. 2002 Feb 28;45(5):1002-18 [11855980.001]
  • [Cites] Leukemia. 1991 Jul;5(7):598-601 [2072744.001]
  • [Cites] Blood. 1992 Nov 15;80(10):2584-93 [1384791.001]
  • [Cites] Mol Cell Biol. 1993 Oct;13(10):6572-85 [7692230.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):459-63 [7507245.001]
  • [Cites] Nature. 1994 Apr 14;368(6472):643-8 [8145851.001]
  • [Cites] Blood. 1994 May 15;83(10):2795-801 [8180375.001]
  • [Cites] N Engl J Med. 1994 Oct 6;331(14):896-903 [8078551.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1762-8 [7703483.001]
  • [Cites] Immunity. 1995 Jul;3(1):147-61 [7621074.001]
  • [Cites] Leukemia. 1995 Aug;9(8):1368-72 [7643626.001]
  • [Cites] Mol Cancer Ther. 2006 Apr;5(4):995-1006 [16648571.001]
  • [Cites] Leukemia. 2006 Aug;20(8):1368-76 [16761017.001]
  • [Cites] Mol Cancer Ther. 2006 Jul;5(7):1774-82 [16891463.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1469-77 [16638934.001]
  • [Cites] Mol Cancer Ther. 2006 Sep;5(9):2378-87 [16985072.001]
  • [Cites] Leuk Res. 2006 Dec;30(12):1541-6 [16603240.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3262-70 [16857985.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3477-83 [16857987.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3674-81 [16902153.001]
  • [Cites] Haematologica. 2007 Jan;92(1):27-34 [17229632.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Feb 1;846(1-2):1-7 [16798122.001]
  • [Cites] Leukemia. 2007 Mar;21(3):439-45 [17205056.001]
  • [Cites] Oncogene. 2002 Apr 11;21(16):2555-63 [11971190.001]
  • [Cites] Blood. 2002 Jun 1;99(11):3885-91 [12010785.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Blood. 2002 Jul 1;100(1):59-66 [12070009.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):421-32 [12124172.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):433-43 [12124173.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4236-43 [12154025.001]
  • [Cites] J Med Chem. 2002 Aug 15;45(17):3772-93 [12166950.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1699-704 [12200684.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2941-9 [12351406.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):327-37 [12538485.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):5148-55 [12435730.001]
  • [Cites] Bioorg Med Chem. 2003 May 1;11(9):2007-18 [12670652.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3164-73 [12468433.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3188-97 [12515727.001]
  • [Cites] Blood. 2003 May 1;101(9):3597-605 [12531805.001]
  • [Cites] Blood. 2003 Jul 15;102(2):646-51 [12663439.001]
  • [Cites] Blood. 2003 Aug 1;102(3):795-801 [12649163.001]
  • [Cites] Blood. 2003 Aug 1;102(3):881-6 [12676789.001]
  • (PMID = 18452067.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA128864; None / None / / R01 CA128864-04; United States / NCI NIH HHS / CA / R01 CA128864-04
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Number-of-references] 127
  • [Other-IDs] NLM/ NIHMS263721; NLM/ PMC3031857
  •  go-up   go-down


88. Karpas A, Harder L, Czepulkowski B, Bloxham D, Saward R, Dremucheva A, Siebert R: Studies of four new human myeloma cell lines. Leuk Lymphoma; 2005 Jan;46(1):101-12
Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Studies of four new human myeloma cell lines.
  • We describe the establishment and studies of four myeloma cell lines that were derived from 2 young individuals with plasma cell leukaemia (Karpas 25 and 1272) and from 2 older persons with multiple myeloma (Karpas 417 and 929).
  • The cultured cells have the ultrastructural appearance of plasma cells with abundant rough endoplasmic reticulum (RER).
  • Their phenotypic profile conform with that of malignant plasma cells.
  • Karyotype analysis revealed that each cell line is unique and all are hyperdipoide with complex aberrant chromosomes.
  • FISH analysis revealed cryptic translocations affecting the IGH locus in 14q32 of 2 of these cell lines.
  • Using R- and G-banding numerous other chromosomal abnormalities were recorded and illustrated in each of the 4 cell lines.
  • [MeSH-major] Leukemia, Plasma Cell / genetics. Leukemia, Plasma Cell / pathology
  • [MeSH-minor] Cell Line, Tumor. Chromosome Banding. Chromosomes, Human / genetics. Endoplasmic Reticulum / ultrastructure. Humans. Immunoglobulins / immunology. Immunoglobulins / metabolism. Karyotyping. Microscopy, Electron. Phenotype

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621787.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulins
  •  go-up   go-down


89. Liedtke M, Medeiros BC: Plasma cell leukemia: concepts and management. Expert Rev Hematol; 2010 Oct;3(5):543-9
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukemia: concepts and management.
  • Plasma cell leukemia (PCL) is a rare and aggressive plasma cell dyscrasia.
  • PCL can present de novo or following a prodrome of plasma cell myeloma.
  • Patients with PCL tend to present with aggressive clinical features, such as extramedullary disease, bone marrow failure, advanced stage disease and expression of distinct immunophenotypic markers, such as lack of CD56 and presence of CD20.
  • The impact of newer agents, such as bortezomib and lenalidomide, in conjunction with autologous and allogeneic stem cell transplantation is uncertain, but emerging data suggest that use of these modalities may help improve the poor prognosis of patients with PCL.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Boronic Acids / administration & dosage. Leukemia, Plasma Cell / therapy. Paraproteinemias / therapy. Pyrazines / administration & dosage. Thalidomide / analogs & derivatives
  • [MeSH-minor] Aged. Antigens, CD20 / analysis. Antigens, CD56 / analysis. Bortezomib. Humans. Multiple Myeloma / mortality. Multiple Myeloma / therapy. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / physiopathology. Neoplasms, Second Primary / therapy. Palliative Care. Prognosis. Stem Cell Transplantation. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21083471.001).
  • [ISSN] 1747-4094
  • [Journal-full-title] Expert review of hematology
  • [ISO-abbreviation] Expert Rev Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD56; 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 4Z8R6ORS6L / Thalidomide; 69G8BD63PP / Bortezomib; F0P408N6V4 / lenalidomide
  •  go-up   go-down


90. Patel RT, Caceres A, French AF, McManus PM: Multiple myeloma in 16 cats: a retrospective study. Vet Clin Pathol; 2005 Dec;34(4):341-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inclusion required an antemortem diagnosis of multiple myeloma using 2 of 4 criteria:.
  • 1) >or=20% plasma cells in the bone marrow, or >or=10% if atypical plasma cells;.
  • Alternatively, a postmortem diagnosis was based on the findings of multiple plasma cell neoplasms, with marrow involvement.
  • Plasma cells were markedly immature, atypical, or both in 10 of 12 (83.3%) cats.
  • The disease in 1 of 2 cats with cutaneous tumors progressed to plasmacytic leukemia.
  • CONCLUSIONS: Common findings in feline multiple myeloma include atypical plasma cell morphology, hypocholesterolemia, anemia, bone lesions, and multi-organ involvement.
  • Based on the results of this study, we advocate modifying diagnostic criteria in cats to include consideration of plasma cell morphology and visceral organ infiltration.

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270258.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Lai AY, Fatemi M, Dhasarathy A, Malone C, Sobol SE, Geigerman C, Jaye DL, Mav D, Shah R, Li L, Wade PA: DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas. J Exp Med; 2010 Aug 30;207(9):1939-50
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas.
  • Aberrant DNA methylation commonly occurs in cancer cells where it has been implicated in the epigenetic silencing of tumor suppressor genes.
  • The BCL6 oncogene is implicated in the pathogenesis of germinal center-derived B cell lymphomas.
  • We demonstrate that the intragenic CpG islands within the first intron of the human BCL6 locus were hypermethylated in lymphoma cells that expressed high amounts of BCL6 messenger RNA (mRNA).
  • Depletion of CTCF by short hairpin RNA in neoplastic plasma cells that do not express BCL6 resulted in up-regulation of BCL6 transcription.

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1995 Jul 1;86(1):28-37 [7795234.001]
  • [Cites] Blood. 1995 Jul 1;86(1):45-53 [7795255.001]
  • [Cites] Mol Cell Biol. 1996 Jun;16(6):2802-13 [8649389.001]
  • [Cites] Nat Genet. 1997 Jun;16(2):161-70 [9171827.001]
  • [Cites] J Biol Chem. 1998 Mar 6;273(10):5858-68 [9488723.001]
  • [Cites] Novartis Found Symp. 1998;214:187-95; discussion 195-9, 228-32 [9601018.001]
  • [Cites] Cell. 1999 Jan 22;96(2):185-93 [9988214.001]
  • [Cites] Trends Genet. 1999 Jan;15(1):34-7 [10087932.001]
  • [Cites] Cell. 1999 Aug 6;98(3):387-96 [10458613.001]
  • [Cites] Nature. 2004 Dec 2;432(7017):635-9 [15577913.001]
  • [Cites] Nat Med. 2004 Dec;10(12):1329-35 [15531890.001]
  • [Cites] Hum Mol Genet. 2005 Apr 15;14 Spec No 1:R65-76 [15809275.001]
  • [Cites] Cell Cycle. 2005 Feb;4(2):239-41 [15655367.001]
  • [Cites] Nat Rev Genet. 2005 May;6(5):403-10 [15818385.001]
  • [Cites] Cancer Cell. 2005 May;7(5):445-55 [15894265.001]
  • [Cites] Nat Genet. 2005 Aug;37(8):853-62 [16007088.001]
  • [Cites] Adv Immunol. 2005;87:163-208 [16102574.001]
  • [Cites] Lab Invest. 2005 Sep;85(9):1172-80 [16025148.001]
  • [Cites] Nat Immunol. 2005 Oct;6(10):1054-60 [16142238.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1412-7 [16432200.001]
  • [Cites] Genome Res. 2006 Feb;16(2):157-63 [16365381.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):107-16 [16491070.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15018-23 [12407182.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6784-7 [12438281.001]
  • [Cites] Cell. 1999 Oct 29;99(3):247-57 [10555141.001]
  • [Cites] Cell. 1999 Nov 24;99(5):451-4 [10589672.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Nature. 2000 May 25;405(6785):482-5 [10839546.001]
  • [Cites] Nature. 2000 May 25;405(6785):486-9 [10839547.001]
  • [Cites] Hum Mol Genet. 2000 Oct;9(16):2395-402 [11005794.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):11-9 [11262868.001]
  • [Cites] Genome Res. 2002 Jun;12(6):996-1006 [12045153.001]
  • [Cites] Immunity. 2002 Jul;17(1):51-62 [12150891.001]
  • [Cites] Annu Rev Immunol. 2003;21:205-30 [12524387.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:213-9 [12724226.001]
  • [Cites] Leukemia. 2003 Jul;17(7):1390-7 [12835729.001]
  • [Cites] Mol Cell. 2004 Jan 30;13(2):291-8 [14759373.001]
  • [Cites] Cell. 2004 Oct 1;119(1):75-86 [15454082.001]
  • [Cites] J Natl Cancer Inst. 1966 Oct;37(4):547-59 [4288580.001]
  • [Cites] Cancer Res. 1985 Jul;45(7):3197-202 [2408746.001]
  • [Cites] Blood. 1986 Jun;67(6):1542-9 [2423157.001]
  • [Cites] J Mol Biol. 1987 Jul 20;196(2):261-82 [3656447.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):435-43 [16766263.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7939-47 [16912168.001]
  • [Cites] Methods Enzymol. 2006;411:270-82 [16939795.001]
  • [Cites] Genes Dev. 2006 Sep 1;20(17):2349-54 [16951251.001]
  • [Cites] J Immunol. 2006 Nov 15;177(10):6930-9 [17082608.001]
  • [Cites] Science. 2007 Feb 23;315(5815):1141-3 [17322062.001]
  • [Cites] Nat Genet. 2007 Mar;39(3):311-8 [17277777.001]
  • [Cites] Cell. 2007 Mar 23;128(6):1231-45 [17382889.001]
  • [Cites] Cell. 2007 May 18;129(4):823-37 [17512414.001]
  • [Cites] Br J Haematol. 2007 Jul;138(1):3-11 [17489980.001]
  • [Cites] Nature. 2007 Jun 14;447(7146):799-816 [17571346.001]
  • [Cites] Nat Immunol. 2007 Jul;8(7):705-14 [17558410.001]
  • [Cites] Cell. 2007 Jul 13;130(1):77-88 [17632057.001]
  • [Cites] Cancer Cell. 2007 Sep;12(3):280-92 [17785208.001]
  • [Cites] Immunol Res. 2007;37(3):177-86 [17873402.001]
  • [Cites] Nat Immunol. 2007 Oct;8(10):1132-9 [17828269.001]
  • [Cites] Epigenetics. 2007 Sep;2(3):161-72 [17965620.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):252-7 [18162535.001]
  • [Cites] Oncogene. 2008 Jan 10;27(3):404-8 [17621273.001]
  • [Cites] Curr Opin Hematol. 2008 Jul;15(4):381-90 [18536578.001]
  • [Cites] Mol Cell. 2008 Oct 10;32(1):129-39 [18851839.001]
  • [Cites] J Comput Biol. 2009 Feb;16(2):317-29 [19193149.001]
  • [Cites] Blood. 2009 Apr 9;113(15):3397-405 [18927431.001]
  • [Cites] Clin Cancer Res. 2009 Jun 15;15(12):3927-37 [19509173.001]
  • [Cites] Nature. 2009 Nov 19;462(7271):315-22 [19829295.001]
  • [Cites] Nat Med. 2009 Dec;15(12):1369-76 [19966776.001]
  • [Cites] Biochem Biophys Res Commun. 2010 Feb 5;392(2):129-34 [20051228.001]
  • [Cites] Nat Genet. 2003 Mar;33 Suppl:245-54 [12610534.001]
  • [Cites] Cancer Res. 1988 Mar 1;48(5):1159-61 [3342396.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1990 Jan 30;326(1235):179-87 [1968655.001]
  • [Cites] Oncogene. 1990 Dec;5(12):1743-53 [2284094.001]
  • [Cites] Nucleic Acids Res. 1991 Aug 11;19(15):4293 [1870982.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Bioessays. 1992 Jan;14(1):33-6 [1546979.001]
  • [Cites] Cell. 1992 Jun 12;69(6):915-26 [1606615.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12):2732-5 [8504412.001]
  • [Cites] Science. 1993 Oct 29;262(5134):747-50 [8235596.001]
  • [Cites] Trends Genet. 1995 Mar;11(3):94-100 [7732579.001]
  • (PMID = 20733034.001).
  • [ISSN] 1540-9538
  • [Journal-full-title] The Journal of experimental medicine
  • [ISO-abbreviation] J. Exp. Med.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / Z01 ES101965; United States / NIDDK NIH HHS / DK / K08 DK060647; United States / Intramural NIH HHS / / ; United States / NIDDK NIH HHS / DK / DK60647; United States / NIEHS NIH HHS / ES / Z01ES101965; United States / NIEHS NIH HHS / ES / Z01 ES101765; United States / NIEHS NIH HHS / ES / Z01ES101765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / CCCTC-binding factor; 0 / DNA-Binding Proteins; 0 / Repressor Proteins
  • [Other-IDs] NLM/ PMC2931164
  •  go-up   go-down


92. Peng KW, Dogan A, Vrana J, Liu C, Ong HT, Kumar S, Dispenzieri A, Dietz AB, Russell SJ: Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. Am J Hematol; 2009 Jul;84(7):401-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.
  • In multiple myeloma, some of the neoplastic plasma cells are diffusely dispersed among the normal bone marrow cells (bone marrow resident), whereas others are located in discrete, well-vascularized solid tumors (plasmacytomas) that may originate in bone or soft tissue.
  • Interactions between bone marrow-resident myeloma cells and bone marrow stromal cells (BMSCs) are important determinants of myeloma pathogenesis.
  • However, little is known of the factors sustaining myeloma growth and cell viability at the centers of expanding plasmacytomas, where there are no BMSCs.
  • The CD68+ tumor-associated macrophages (TAM) accounted for 2-12% of nucleated cells and were evenly distributed through the parenchyma.
  • The TAM generally had dendritic morphology, and each dendrite was in close contact with multiple plasma cells.
  • To determine whether cells of the monocytic lineage might be exploitable as carriers for delivery of therapeutic agents to plasmacytomas, primary human CD14+ cells were infected with oncolytic measles virus and administered intravenously to mice bearing KAS6/1 human myeloma xenografts.
  • The cell carriers localized to KAS6/1 tumors, where they transferred MV infection to myeloma cells and prolonged the survival of mice bearing disseminated human myeloma disease.

  • Genetic Alliance. consumer health - Measles.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2000 Sep;74(17):7972-9 [10933705.001]
  • [Cites] J Hematother Stem Cell Res. 2000 Feb;9(1):95-101 [10738977.001]
  • [Cites] Leukemia. 2008 Dec;22(12):2261-4 [18509356.001]
  • [Cites] Gene Ther. 2008 May;15(10):753-8 [18356814.001]
  • [Cites] Gene Ther. 2008 May;15(10):797-806 [18356812.001]
  • [Cites] Expert Opin Biol Ther. 2008 Apr;8(4):463-73 [18352850.001]
  • [Cites] Oncogene. 2008 Jan 24;27(5):663-74 [17667938.001]
  • [Cites] Clin Pharmacol Ther. 2007 Dec;82(6):700-10 [17971816.001]
  • [Cites] Nat Rev Cancer. 2007 Aug;7(8):585-98 [17646864.001]
  • [Cites] Br J Haematol. 2007 Apr;137(2):133-41 [17391493.001]
  • [Cites] Exp Hematol. 2007 Apr;35(4 Suppl 1):155-62 [17379101.001]
  • [Cites] Gene Ther. 2007 Feb;14(4):324-33 [17051248.001]
  • [Cites] Transfusion. 2006 Dec;46(12):2083-9 [17176319.001]
  • [Cites] Mol Ther. 2007 Jan;15(1):123-30 [17164783.001]
  • [Cites] Mol Ther. 2007 Jan;15(1):114-22 [17164782.001]
  • [Cites] J Leukoc Biol. 2006 Dec;80(6):1183-96 [16997855.001]
  • [Cites] Am J Hematol. 2006 Sep;81(9):649-56 [16845660.001]
  • [Cites] Br J Haematol. 2000 Dec;111(4):1035-44 [11167737.001]
  • [Cites] Blood. 2001 Oct 1;98(7):2002-7 [11567982.001]
  • [Cites] J Pathol. 2002 Mar;196(3):254-65 [11857487.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2210-6 [12114422.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2142-7 [12357369.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):903-11 [12826882.001]
  • [Cites] Br J Haematol. 2003 Nov;123(4):631-6 [14616966.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):4079-83 [14666722.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6a):4395-409 [14666727.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):71-8 [14708027.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1641-6 [14604966.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2016-23 [15026338.001]
  • [Cites] Semin Cancer Biol. 2004 Jun;14(3):155-60 [15246050.001]
  • [Cites] Hum Gene Ther. 2004 Sep;15(9):821-31 [15353037.001]
  • [Cites] Immunol Today. 1992 Jul;13(7):265-70 [1388654.001]
  • [Cites] Blood. 1997 Dec 1;90(11):4278-82 [9373238.001]
  • [Cites] Br J Haematol. 1999 May;105(2):441-4 [10233418.001]
  • [Cites] Cytotherapy. 2004;6(6):563-70 [15773024.001]
  • [Cites] Oncology (Williston Park). 2005 Jul;19(8):983-4, 986 [16131042.001]
  • [Cites] Immunity. 2005 Oct;23(4):344-6 [16226499.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):717-27 [16520032.001]
  • [Cites] Exp Hematol. 2006 Jun;34(6):713-20 [16728275.001]
  • [Cites] J Exp Med. 2006 Aug 7;203(8):1859-65 [16880256.001]
  • (PMID = 19507209.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA129996; United States / NCI NIH HHS / CA / CA100634; United States / NCI NIH HHS / CA / CA129966-02; United States / NCI NIH HHS / CA / R01 CA129966; United States / NCI NIH HHS / CA / R01 CA100634; United States / NCI NIH HHS / CA / R01 CA129966-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD14; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human
  • [Other-IDs] NLM/ NIHMS166210; NLM/ PMC2805200
  •  go-up   go-down


93. Muñoz A, Riber C, Trigo P, Castejón F: Hematopoietic neoplasias in horses: myeloproliferative and lymphoproliferative disorders. J Equine Sci; 2009;20(4):59-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leukemia, i.e., the neoplasia of one or more cell lines of the bone marrow, although less common than in other species, it is also reported in horses.
  • Leukemia can be classified according to the affected cells (myeloproliferative or lymphoproliferative disorders), evolution of clinical signs (acute or chronic) and the presence or lack of abnormal cells in peripheral blood (leukemic, subleukemic and aleukemic leukemia).
  • The main myeloproliferative disorders in horses are malignant histiocytosis and myeloid leukemia, the latter being classified as monocytic and myelomonocytic, granulocytic, primary erythrocytosis or polycythemia vera and megakaryocytic leukemia.
  • The most common lymphoproliferative disorders in horses are lymphoid leukemia, plasma cell or multiple myeloma and lymphoma.
  • Lymphoma is the most common hematopoietic neoplasia in horses and usually involves lymphoid organs, without leukemia, although bone marrow may be affected after metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24833969.001).
  • [ISSN] 1340-3516
  • [Journal-full-title] Journal of equine science
  • [ISO-abbreviation] J Equine Sci
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC4013965
  • [Keywords] NOTNLM ; anemia / blood / clinical pathology / horses / leukemia
  •  go-up   go-down


94. Martin P, Santón A, García-Cosio M, Bellas C: hMLH1 and MGMT inactivation as a mechanism of tumorigenesis in monoclonal gammopathies. Mod Pathol; 2006 Jul;19(7):914-21
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Monoclonal gammopathies are a group of disorders characterized by clonal proliferation and accumulation of immunoglobulin-producing plasma cells.
  • Multiple myeloma and monoclonal gammopathy of undetermined significance are the most common monoclonal gammopathies; the two comprise a spectrum of disorders, ranging from a relatively benign disease, monoclonal gammopathy of undetermined significance, to a malignant disease, multiple myeloma.
  • With the purpose of studying the gene silencing of MGMT and hMLH1 in plasma cell disorders, we investigated the methylation status and expression of both genes in: 29 cases of multiple myeloma; one case of plasma cell leukaemia; 13 cases of monoclonal gammopathy of undetermined significance; and two cases of polyclonal plasmacytosis, using methylation-specific polymerase-chain reaction and immunohistochemical techniques.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction. Promoter Regions, Genetic / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607377.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


95. Chang H, Qi X, Jiang A, Xu W, Young T, Reece D: 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant; 2010 Jan;45(1):117-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1p21 status was also evaluated in 16 patients with monoclonal gammopathy of undetermined significance (MGUS) and 41 patients with plasma cell leukemia (PCL).
  • Our results indicate that del(1p21) is an independent poor prognostic factor associated with disease progression in MM.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Gene Amplification. Hematopoietic Stem Cell Transplantation. Humans. In Situ Hybridization, Fluorescence. Leukemia, Plasma Cell / genetics. Male. Middle Aged. Multivariate Analysis. Paraproteinemias / genetics. Prognosis. Sequence Deletion

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19448682.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


96. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM: Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol; 2010 Apr 10;28(11):1856-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
  • PURPOSE To determine the efficacy and toxicity of the combination of sorafenib, cytarabine, and idarubicin in patients with acute myeloid leukemia (AML) younger than age 65 years.
  • RESULTS Overall, 38 (75%) patients have achieved a complete remission (CR), including 14 (93%) of 15 patients with mutated FMS-like tyrosine kinase-3 (FLT3; the 15th patient had complete remission with incomplete platelet recovery [CRp]) and 24 (66%) of 36 patients with FLT3 wild-type (WT) disease (three additional FLT3-WT patients had CRp).
  • Plasma inhibitory assay demonstrated an on-target effect on FLT3 kinase activity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2009 Jun 25;113(26):6567-71 [19389879.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3938-46 [19029442.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2434-9 [11290608.001]
  • [Cites] Br J Haematol. 2001 Jun;113(4):983-8 [11442493.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1752-9 [11535508.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7233-9 [11585760.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Blood. 2002 Jul 1;100(1):59-66 [12070009.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):413-5 [12124170.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1532-42 [12176867.001]
  • [Cites] Curr Pharm Des. 2002;8(25):2269-78 [12369855.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4372-80 [12393388.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):535-50 [12576416.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):650-65 [12951584.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1738-52 [12970773.001]
  • [Cites] Blood. 2004 Jan 1;103(1):267-74 [12969963.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2266-75 [14604974.001]
  • [Cites] Blood. 2004 May 15;103(10):3669-76 [14726387.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] Blood. 2004 Aug 15;104(4):1145-50 [15126317.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1841-9 [15166029.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1855-8 [15178581.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Blood. 1992 Nov 15;80(10):2584-93 [1384791.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1089-96 [8562934.001]
  • [Cites] Leukemia. 1996 Dec;10(12):1911-8 [8946930.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4202-9 [15304385.001]
  • [Cites] Blood. 2005 Jan 1;105(1):335-40 [15345593.001]
  • [Cites] Blood. 2005 Jan 1;105(1):54-60 [15345597.001]
  • [Cites] Blood. 2005 Jan 1;105(1):22-30 [15358622.001]
  • [Cites] Blood. 2005 May 1;105(9):3679-85 [15626738.001]
  • [Cites] Blood. 2006 Jan 1;107(1):293-300 [16150941.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1090-8 [16435386.001]
  • [Cites] Blood. 2006 May 1;107(9):3700-7 [16410449.001]
  • [Cites] Blood. 2006 Jul 1;108(1):405-6; author reply 406 [16790588.001]
  • [Cites] Leukemia. 2006 Nov;20(11):2074-6 [16990788.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3262-70 [16857985.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3477-83 [16857987.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3494-503 [16868253.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3674-81 [16902153.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:178-84 [17124058.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1643-52 [17047150.001]
  • [Cites] Leuk Res. 2007 Jun;31(6):791-7 [17156841.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1262-70 [17456725.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3547-51 [17673605.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4476-9 [17827387.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1552-9 [17940205.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 6;100(3):184-98 [18230792.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2776-84 [17957027.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2527-37 [17965322.001]
  • [Cites] Leukemia. 2008 Apr;22(4):808-18 [18200035.001]
  • [Cites] Blood. 2008 Jul 15;112(2):444-5; author reply 445 [18606888.001]
  • [Cites] Leuk Lymphoma. 2008 Dec;49(12):2246-55 [19052971.001]
  • [Cites] Oncogene. 2000 Feb 3;19(5):624-31 [10698507.001]
  • (PMID = 20212254.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA100632; United States / NCI NIH HHS / CA / R01 CA128864; United States / NCI NIH HHS / CA / R01 CA128864-04
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 04079A1RDZ / Cytarabine; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; ZRP63D75JW / Idarubicin
  • [Other-IDs] NLM/ PMC2930809
  •  go-up   go-down


97. Abe M, Yokoyama H, Tohmiya Y, Okitsu Y, Ohguchi H, Kohata K, Yamamoto J, Onishi Y, Ishizawa K, Kameoka J, Harigae H: Plasma cell leukemia maintaining complete remission by syngeneic stem cell transplantation combined with low-dose thalidomide maintenance therapy. Intern Med; 2009;48(20):1833-5
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukemia maintaining complete remission by syngeneic stem cell transplantation combined with low-dose thalidomide maintenance therapy.
  • Plasma cell leukemia (PCL) is a rare variant of multiple myeloma, which is very aggressive and resistant to chemotherapy.
  • We report a case of PCL successfully treated with syngeneic peripheral blood stem cell transplantation followed by low-dose thalidomide.
  • The clinical course of the present case suggests that autologous stem cell transplantation using a graft with reduced contamination of malignant cells followed by low-dose thalidomide maintenance therapy may improve the PCL treatment outcome.
  • [MeSH-major] Leukemia, Plasma Cell / diagnosis. Stem Cell Transplantation. Thalidomide / administration & dosage

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19834277.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


98. DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC: Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood; 2006 Dec 1;108(12):3674-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
  • Because of the correlation between FLT3 internal tandem duplication (ITD) mutations and poor prognosis in acute myelogenous leukemia (AML), we conducted a phase 1 trial of tandutinib in 40 patients with either AML or high-risk myelodysplastic syndrome (MDS).
  • Tandutinib's pharmacokinetics were characterized by slow elimination, with achievement of steady-state plasma concentrations requiring greater than 1 week of dosing.


99. Ramsingh G, Mehan P, Luo J, Vij R, Morgensztern D: Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer; 2009 Dec 15;115(24):5734-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004.
  • BACKGROUND: Primary plasma cell leukemia (PCL) is a rare plasma cell disorder, and current knowledge regarding survival in this disease is limited to small series of patients.
  • The median overall survival (OS) was 4 months and the median disease-specific survival (DSS) was 6 months for patients with PCL; the 1-year, 2-year, and 5-year OS rates were 27.8%, 14.1%, and 6.4%, respectively.
  • [MeSH-major] Leukemia, Plasma Cell / mortality
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Multiple Myeloma / mortality. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • (PMID = 19877113.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Oka S, Yokote T, Akioka T, Hara S, Yamano T, Tsuji M, Hanafusa T: Successful treatment of multi-agent chemotherapy with rituximab for IgM plasma cell leukemia. Leuk Res; 2006 Dec;30(12):1581-3
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of multi-agent chemotherapy with rituximab for IgM plasma cell leukemia.
  • The laboratory findings showed increased white blood cells at 11.37 x 10(3)cells/microl with 26.5% abnormal cells, low haemoglobin and, elevated creatinine, although serum lactate dehydrogenase and calcium levels were normal.
  • Bone marrow aspiration showed 59.5% infiltration of abnormal cells that were characterized by typical mature plasmacytoid morphology.
  • Abnormal cells expressed surface CD20, surface CD138, and cytoplasmic IgM, but not surface CD56 nor surface IgM by flow cytometric immunophenotyping with CD38 gating.
  • The clinical findings led to the diagnosis of the IgM Plasma cell leukemia (PCL).
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant / methods. Immunoglobulin M / blood. Leukemia, Plasma Cell / drug therapy

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540168.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunoglobulin M; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down






Advertisement